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This dissertation is a compilation of work in which selected analytical methods, including 
fast-scan cyclic voltammetry at carbon-fiber microelectrodes (FSCV), were used to determine 
neurotransmitter release and uptake properties in animals that model neurodegenerative disease 
and neurotoxicity. Alterations in the release and uptake of dopamine (DA), a central nervous 
system neurotransmitter that plays an important role in motor function and cognition, could 
contribute to, as well as be a consequence of, abnormal syndromes associated with 
neurodegeneration and neurotoxicity. First, we describe the application of FSCV to measure DA 
release and uptake in animals that model post chemotherapy cognitive impairment (PCCI). PCCI 
is a complication of chemotherapy treatment that is characterized by a general decline in 
cognition affecting visual and verbal memory, attention, complex problem solving skills, and 
motor function. It is estimated that one third of patients who undergo chemotherapy treatment 
will experience cognitive impairment. To investigate how chemotherapy treatment affects these 
systems, FSCV at carbon-fiber microelectrodes was used to measure dopamine release and 
uptake in coronal brain slices of the striatum. Here, we report on two PCCI studies with rats 
treated with carboplatin or a cocktail containing cyclophosphamide, methotrexate, and 5-
fluorouracil (CMF), both of which are composed of clinically relevant chemotherapeutic 
compounds. Measurements were taken from rats treated weekly with selected doses of 
chemotherapeutic agent and from control rats treated with saline.  It was found that DA release 
in the striatum is attenuated in chemotherapy-treated rats. Nevertheless, overall dopamine 
content, measured in striatal brain lysates by high performance liquid chromatography, and 
reserve pool DA, measured by FSCV after pharmacological manipulation, did not significantly 
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change, suggesting that chemotherapy treatment impairs the dopamine release and uptake 
processes. 
Second, we report on regional differences in DA dysregulation in transgenic 
Huntington’s disease model mice. Huntington’s disease (HD) is a fatal, neurodegenerative 
movement disorder that is characterized by degeneration of the striatum. It has been determined 
previously that electrically-evoked dopamine (DA) release is severely attenuated in the 
dorsolateral striatum of R6/2 HD model mice. Here, we have used fast-scan cyclic voltammetry 
to uncover regional differences of DA release in the striatum of R6/2 mice. We found a dorsal-
to-ventral progressive gradient in single pulse DA release in 6 to 14 week-old R6/2 mice. 
Moreover, when applying a 120 stimulation pulse-train, we found that DA release was only 
significantly attenuated in the dorsal striatum. In order to see if regional differences of release 
were caused by the density of viable dopamine terminals, autoradiographic labeling of the 
dopamine transporter (DAT) with [
3
H]WIN 35,428 was performed. It was found that the density 
distribution of DAT is significantly less in R6/2 mice in comparison to their WT controls; 
however, there were no significant regional differences. These data collectively suggest that the 
genetic mutation involved in HD leads to the increased vulnerability of the dorsal striatum in 
comparison to the ventral striatum, therefore providing insight to the disease mechanism  
The final project presented here involves the development of a method to combine FSCV 
measurements with caged compound photo-activation. Caged compounds have been used 
extensively to investigate neuronal function in a variety of preparations, including cell culture, ex 
vivo tissue samples, and in vivo. We describe electrochemical measurements used to determine 
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Chapter 1: Introduction 
  
Understanding the detailed mechanisms involved in neurodegenerative disease and 
neurotoxic events is of critical importance in modern medicine. The ability to detect molecules 
involved in neuronal signaling has long since been deemed important by the bioanalytical 
community. For the last 50 years, voltammetry has proven to be a useful method in performing 
such research. Since its advent, many subsets of voltammetry have been developed to improve 
the ability to detect and quantify different classes of electroactive biomolecules. Fast-scan cyclic 
voltammetry at carbon-fiber microelectrodes (FSCV) is one such method that has been 
developed and has gained the favor of neuroscientists and analytical chemists for its low limits of 




1.1 Electrochemical methods 
 
1.1.1 Voltammetry  
Voltammetry is a dynamic electroanalytical method that provides information about an 
analyte by measuring current as a function of an applied potential to an electrode surface. A 
voltammetric experiment requires at least two electrodes, a working electrode and reference 
electrode. As the potential at the surface of the working electrode is varied, a faradaic current 
response, due to analyte oxidation or reduction, is measured by an ammeter and plotted versus 
applied potential. A possible complication of carrying out voltammetry measurements with 
conventionally-sized electrodes is a drop in applied voltage at larger currents (µA or greater) in 
highly resistive solutions (kOhm or greater). This phenomenon, known as IR drop, is governed 
by Ohm’s Law, E = IR where I is current and R is the solution resistance.  The consequence of 
this potential drop is a distortion in the voltammogram. To diminish the effects of IR drop, a 
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three-electrode system is typically used when conventional voltammetry measurements are 
obtained. The three-electrode system uses an auxiliary electrode in addition to the working and 
reference electrodes. An auxiliary electrode is typically made of chemically inert metal, such as 
platinum, that allows for current to pass between the working electrode and itself. A schematic of 
a three electrode system can be seen in Figure 1. 
 
 
Figure 1.  General schematic diagram of a three electrode system.  The working, counter and 
reference electrodes are labeled.  A represents an ammeter for measuring the current. V 




















1.1.2 Cyclic Voltammetry  
Cyclic voltammetry is among the most widely used electrochemical techniques and has 
been extensively applied to the fields of inorganic chemistry, organic chemistry, and 
biochemistry
4
 due to its ability to qualitatively and quantitatively measure redox chemistry at an 
electrode surface. In cyclic voltammetry, the potential is increased from a holding potential up to 
the switching potential, seen as the highest voltage point in the waveform in Figure 1, and is then 
decreased back to the holding potential. This potential at the working electrode surface is 
controlled by comparison to a reference electrode As the waveform is applied, any redox events 
can be measured by as a current response. A plot of this current response measured at the 
working electrode against the applied voltage yields a cyclic voltammogram (CV). A CV 
provides a researcher with chemical information that includes redox mechanistic information, 
kinetic information, and can also be used to positively confirm the presence of the analyte of 
interest. 
Two types of faradaic currents are detected using CV: anodic and cathodic. An anodic 
current is detected when analyte is oxidized as the peak potential in the waveform is approached. 
A cathodic current is detected during molecular reduction as the holding potential is approached. 
These two currents have different polarities due to opposing flow of electrons, so they peak on 
differing sides of the CV.
4
 More information will be given on this in section 1.1.3, Fast-Scan 
Cyclic Voltammetry.  
 There are four classes of redox reactions that may occur at the electrode surface when 
performing CV: reversible, quasi-reversible, irreversible, and chemically irreversible reactions. 
Reversible redox reactions proceed such that there is an equilibrium established between the rate 
of oxidation and reduction at the surface of the working electrode. Electrochemical reversibility 
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depends on the rate of electron transfer between the electroactive species and the working 
electrode. A redox reaction is electrochemically reversible when the electron transfer occurs 
rapidly (ks > 0.02 cm/s) without thermodynamic barriers.
5 
To be considered electrochemically 
reversible, the observed difference between the oxidation and reduction potentials (as determined 
by the peaks in the CV) must be less than 0.058 Volts/n, where n is the number of electrons 
transferred per redox reaction.
5
 When rate of electron transfer between the analyte and the 
working electrode is slow (ks < 5 x 10
-5
 cm/s), the reaction is electrochemically irreversible. 
Redox reactions with intermediate rates of electron transfer are considered to be quasi-reversible.    
A reversible reaction taking place at the electrode surface will obey the Nernst Equation. 
  








The Nernst equation describes how the concentrations of the oxidized and reduced species 
change as a function of the applied excitatory potential (E) where 𝐸𝑜 is the formal reduction 
potential of the analyte, R is the universal gas constant, n is the number of electrons per reaction, 
and F is the faraday constant.
4
   
  






If the electron transfer of the redox reaction is sufficiently fast, the current measured at the 
electrode surface in response to the applied potential can be described by the Cottrell equation 
(Equation 2) where i is the current (A), n is the number of electrons transferred 
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(equivalents/mol), F is the Faraday constant, A is the area of the electrode, cj
0
 is the initial 
analyte concentration, Dj is the diffusion coefficient, and t is time.  
 The ability to stimulate and measure redox reactions as a function of the applied potential 
at an electrode surface has been of key importance to analytical chemists. To put it simply, the 
faradaic current response, whether it be oxidative or reductive (depending on the applied 
waveform), will be directly proportional to the concentration of the species. Cyclic voltammetry 
therefore provides a means to quantify electrically-active analytes.  
 
1.1.3 Background-Subtracted Fast-scan Cyclic Voltammetry 
 Fast scan cyclic voltammetry (FSCV) is the most widely used method for the  real-time 
quantification of biogenic amines.
6
 Conventional CV experiments typically employ a potential at 
a scan rate of 100 mV/s while FSCV typically employs a scan rate in the 100-800 V/s range. 
Like conventional CV, in FSCV a linear sweep triangular waveform is applied to the working 
electrode with a controlled holding potential, which is the lowest voltage on the waveform, and a 
switching potential, which represents the highest voltage on the waveform.  
The rapid scan rates applied in FSCV offer sub-second temporal resolution, which has 
made the method applicable to studying the rapid µM concentration changes involved in 
neuronal signaling. It is this feature, along with the high spatial resolution of microelectrodes, 
that has led FSCV to be extensively used to measure DA dynamics in neuronal tissue.
6–18
 The 
description of FSCV as applied to the detection of DA will be the focus of this subsequent 
section. Applications of FSCV have been employed both in vivo in awake rats 
10,19
 and in rodent 
brain slices.
20–22
 The applied waveform can be tailored for the detection of specific analytes. For 
example, DA oxidizes at approximately 0.6 V,
21
 while many other electroactive species (e.g. 
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adenosine and hydrogen peroxide) oxidize at potentials above 1V.
23,24
 Therefore, the waveform 
chosen goes to a high-enough switching potential to sufficiently oxidize DA while avoiding the 
oxidation of other possible interferents.  
  
   
  
 
Figure 1: Typical Waveform applied For DA detection via FSCV.  
 
 
As the potential at the working electrode becomes more positive, the surface becomes 
increasingly electron deficient. Upon reaching a voltage threshold, typically around +0.6 V 
(versus Ag/AgCl electrode), DA is oxidized to dopamine-o-quinone. This two-electron oxidation 
produces a faradaic current that is proportional to the amount of analyte present at the electrode 
surface. Similarly, a current is produced on the backsweep by the reduction of the dopamine-o-
quinone. A typical waveform applied to a carbon-fiber microelectrode when detecting neuronal 
DA release consists of applying a triangular waveform ranging from -0.4V to +1.0V and back to 
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-0.4V (Fig. 1). A typical CV obtained for the oxidation and reduction of DA can be seen in 
Figure 2. 







Figure 2: Cathodic and anodic currents measured with FSCV. Top, electrochemical reaction 
of dopamine oxidation and dopamine-o-quinone reduction. Bottom typical Cyclic 
voltammogram for DA oxidation and reduction.  
 
 
Important features of the CV show the oxidation of DA near +0.6 V and the reduction at -
0.2 V. This CV is characteristic of DA and is used as a “signature” in order to confirm the 
presence of DA. Quantification of analyte can be accomplished via flow-cell analysis calibration 
exploiting the direct relationship between current response and analyte concentration at the 
electrode surface.   
One challenge of FSCV is that the rapid scan rates employed in FSCV lead to a large 
non-faradaic charging currents that are caused by rapid formation of the electrical double layer. 
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It is, therefore, imperative to be able to subtract the charging current to adequately reveal the 
faradaic current of interest within the CV. Fortunately, the charging current is consistent between 
scans and can be successfully subtracted out, allowing for the quantitative measurement of the 
faradaic current. Analyte detection and quantification is only possible after successful 
background subtraction.
4








Figure 3: Background subtraction to obtain the cyclic voltammogram of dopamine. Subtracting 
the background signal (B) from the combined background and DA signal (A) reveals the cyclic 





Background + DA Signal  





 A microelectrode is defined as an electrode with an electroactive surface on the µm scale 
(typically less than 25 µm in diameter).
25,26
 Microelectrodes offer several advantages compared 
to conventional electrodes, including the ability to measure very small currents (below pA range 
in some instances), a small error contribution due to ohmic drop, minimization of the capacitive 
current when compared to conventionally “large” electrodes, and a rapid establishment of 
steady-state mass-transfer.
 24
 Moreover, the small electrode size minimizes perturbation of 
biological systems.   
 Microelectrodes were first used to probe biological systems in the 1940s for the 
amperometric detection of oxygen in tissues.
27
 Despite being successfully used in a wide variety 




 Microelectrodes have been fabricated using multiple materials and geometries. Some 
common electrode geometries include cylinders, disks, rings, and bands.
25
 Cylindrical and disk 
electrodes are typically made from metal micro-wires such as gold and platinum or carbon fibers. 
Band and ring electrodes are typically manufactured via lithography
30
 or by the deposition of 
films and foils.
31,32
 Each electrode geometry provides its own advantages and disadvantages. 
Diffusion is of concern when choosing an appropriate electrode geometry and each option is 
accompanied with its own rigorous mathematics describing this mass transport.
5
 In these studies, 






1.2.1 Carbon-Fiber Microelectrodes 
 Carbon-fiber microelectrodes (CMFE) have several characteristics that make them useful 
for obtaining measurements in brain tissue. From our experience, the sides of the carbon-fiber 
that we used are resistive to electrode fouling. CFMEs also have the possibility of surface 
modification which is not possible with many other  types of materials. This property has been 
exploited to improve sensitivity, selectivity, and temporal resolution.
 35
 Another advantage, as 
touched upon in the previous section regarding general microelectrodes, is that carbon-fibers 
used for the fabrication of CFMEs are typically between 5-10µm in diameter, which minimally 
perturb the tissue and provides high temporal and spatial resolution.
33
 The electrodes used in 
these studies are 5 to 7 µm in diameter and are made from carbon-fiber purchased from 
Goodfellow Cambridge Ltd. (Huntingdon, England). In the subsequent sections and chapters, the 
unmodified cylindrical CFME will be the primary analytical probe used. 
 Although a more detailed account of electrode fabrication can be found in the Materials 
and Methods sections of the subsequent chapters, a general fabrication description shall be noted 
here. CFMEs are made by first aspirating a single carbon fiber into a glass capillary. The glass is 
then pulled via an electrode puller to form two electrodes. After pulling, the carbon fiber is 
manually trimmed to a desired length from the end of the glass capillary (typically 30µm). In 
order to ensure a proper seal, these electrodes are dipped into an epoxy resin solution, dipped in 
toluene to remove excess epoxy resin, and baked to properly cure and establish a true seal. An 
electron micrograph of the end of a CFME can be seen in Figure 4. 










The application of electrochemical methods for the measurement of electroactive 
biomolecules in vivo was pioneered by Ralph N Adams at the University of Kansas. This 
application not only required a sound knowledge of analytical chemistry, but also required the 
ability to apply it to arguably one of the most complex environments in the universe (please 
excuse my grandiosity). In order to interpret information obtained from neurotransmitter release 
measurements, one must first understand the neuron itself. Although neurons vary widely in their 






collection and relaying of signals, contain certain general features. In the simplest of terms, a 
neuron contains a cell body and external projections that are used for communication. These 
projections are dendrites, which surround the cell body and are responsible for receiving input, 
and axons, which are responsible for signal output. In order to propagate a signal, a neuron’s 
specialized ion channels will open, causing the negatively charged intercellular space to 
depolarize. If this depolarization crosses a threshold, it will cause an action potential that will 
rapidly propagate (exceeding 50m/s) along the length of the axon, leading to exocytosis of 
neurotransmitters into the synaptic cleft.
37
 The primary analyte of interest that we measure with 
FSCV is DA. Upon release into the synaptic clef, DA can either interact with post-synaptic or 
pre-synaptic receptors, be taken up into the neuron by the DA transporter, or diffuse out of the 
synaptic cleft. DA that diffuses out of the synaptic cleft is available to be detected 
electrochemically.   
 
1.4 Dopamine 
  DA is a central nervous system (CNS) neurotransmitter involved in many neurological 




 and locomotor control.
35
  Alterations 
in DA system function have been associated with many neurological disorders or outcomes that 
include chemically induced oxidative insult,
19
 genetic modifications that model oxidative 
stress,
36
 and neurodegenerative disease.
19,37–42
 The study of how the DA system is altered in 
neurological disease or toxic events therefore may provide insight into the underlying 
mechanisms of the disease or disorder. Such insight provides valuable information that may lead 
to potential points of therapeutic intervention.  The rest of this section will be dedicated to the 
relevant information regarding the dopaminergic system relevant to the studies discussed in the 
following chapters.  
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1.4.1 Dopamine Synthesis   
 DA synthesis occurs in the cytosol of the dopaminergic neuron, where biosynthesis 
begins from tyrosine. Tyrosine is supplied by dietary protein and makes its way to the brain via 
the blood stream. Upon crossing the blood-brain-barrier (BBB), tyrosine enters the dopaminergic 
neuron. Within the cytosol of the dopaminergic neuron, tyrosine is first converted to 
dihydroxyphenylalanine (L-DOPA) via the enzyme tyrosine hydroxylase (TH). It is important to 
note that this catalytic conversion is the rate limiting step in the synthesis of DA. L-DOPA is 
then converted to DA via the enzyme aromatic amino acid decarboxylase (AADC, dopa 
decarboxylase).
43









Figure 5. The biosynthesis of DA.  
 
1.4.2 Dopamine Storage, Release, and Reuptake      
 Cytosolic DA is packaged into synaptic vesicles by the vesicular monoamine transporter 
(VMAT). Within each vesicle, the concentration of DA is roughly one to three orders of 
magnitude larger than the concentration within the cytosol (≈ 0.1M).
43
 Within the neuron, the 
synaptic vesicles are held within three different pools. The generalized three-pool model of 
neurotransmitter-containing vesicles within neurons consists of a readily releasable pool, a 
recycling pool, and a reserve pool.
44–46
 The readily releasable pool contains only 1-2% of 
vesicles within a neuron.
46
 After depleting the readily releasable pool vesicles, they are 
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replenished by the recycling pool, which accounts for 5-20% of the total number of vesicles 
within the neuron.
47–49
 The reserve pool contains 80-90% of the total number of vesicles within a 
neuron and is thought to be mobilized in response to increased levels of synaptic activity.
44–46
 





Figure 6. The three pool-pool model of DA vesicular storage 
 
Upon receiving an action potential, the neuron undergoes specific protein conformation 
changes leading to the influx of Ca
+
 which leads to the release of DA via exocytosis.
43,50
 Upon 
release, DA enters the post-synaptic cleft where it may interact with DA receptors that are 
present on a postsynaptic target cell or on the presynaptic membrane. The DA receptor will be 
further discussed in more detail in section 1.4.3.  
The ability to terminate DA neurotransmission is relegated to the high-affinity dopamine 
transporter (DAT), which  is present on the terminals of dopaminergic neurons and is responsible 
for removing DA from the extracellular environment.
51
 The DAT is an 80 kDa protein that has 
12 transmembrane segments and is a sodium and calcium dependent transporter.
52
 Much interest 
has been given to the DAT in the past as it is the target for a series of compounds with 
Recycling Pool (5-20% of vesicles) 
Readily Releasable Pool (~1% of vesicles) 
Reserve Pool (80-90% of vesicles) 
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pharmacological promise. Certain compounds that resemble DA, such as amphetamine, are 
readably taken up by the DAT which leads to an increase in DA release and a stimulatory 
effect.
53,54
 The DAT is also an extremely high affinity target for the highly addictive stimulant, 
cocaine, which effectively inhibits DAT leading to the extraneuronal build-up of DA.
55
 The DAT 
has been given much attention from researchers as alterations in its function prove to have 
profound neurological consequences.  A representative image describing the process od DA 






Figure 7. Dopamine release and reuptake.   
 
1.4.3 Dopamine Receptors 
 Dopamine receptors are made up of two general types, known as D1 and D2 . There have 
been 6 different DA receptors identified within these two classes. The D1 class includes receptors 
D1 and D5 while the D2 class includes receptors D2short, D2long, D3, and D4. The D1 and D2 classes 
19 
 
of DA receptors differ in how they affect adenylyl cyclase (AC) activity. The D1-like receptors 
stimulate AC activity whereas D2-like generally inhibit it.
43
 All DA receptors are G protein-
coupled receptors (GPCRs) and each subtype contains considerable homology within their 
primary structure.
56,57
 For a more in-depth look into the complex and well-studied intricacies of 
the DA receptor please see the review by Missale et al.
57
  
 The receptor of interest relevant to the research described in this dissertation is the DA 
autoreceptor. An autoreceptor is a receptor expressed on a neuron that is sensitive to the 
neurotransmitter released by that same neuron. DA autoreceptor activation is one of the principal 
mechanisms of DA regulation. These autoreceptors tend to be expressed both on the axonally 
and dendritically on dopaminergic neurons and therefore respond to both dendritic and terminal 
release. It can generally be said that all DA autoreceptors are D2-like and involve the inhibition 
of AC. Stimulation of DA autoreceptors therefore tends to inhibit DA release, although their 
mechanism of doing so varies by location. For instance, dendritic autoreceptor stimulation 
generally reduces the neuronal firing rate whereas terminal autoreceptor stimulation generally 
inhibits DA synthesis or release.
43
 The DA receptors are represented in Figure 7.         
 
1.4.4 Dopamine Metabolism     
 Dopamine metabolism occurs through catalysis by some common enzymes found in the 
neuronal environment. The location and route of DA metabolism varies and is dependent on the 
cell type and brain region. The key enzymes responsible for the metabolism of DA are  
monoamine oxidase (MAO), aldehyde dehydrogenase (ALDH), and catechol-O-methyl 
transferase (COMT). Figure 7 shows the common metabolites generated by the COMT and 
MAO catalysis of DA. These include dihydroxyphenylacetic acid (DOPAC), homovanillic acid 
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(HVA), 3.4-dihydroxyphenylethanol (DOPET), and 3-methoxy-4-hydroxyphenylethanol 
(MOPET). Although there are quite a few metabolites of DA, DOPAC and HVA are the most 












1.4.5 Relevant Anatomy  
 All of the studies discussed in the subsequent chapters of this dissertation include using 
FSCV to measure DA release in the striatum of rodents. The striatum is the principal sub-nuclei  
of the basal ganglia, which contains a group of subcortical nuclei located in the forebrain.
58,59
 
The components of the dorsal basal ganglia include the striatum, the globus pallidus (GP), the 
entopeduncular nucleus (EP), the subthalamic nucleus (STN), the substantia nigra pars compacta 
(SNc), and the substantia nigra pars reticulate (SNr).
58
 The ventral components of the basal 
ganglia include the nucleus accumbans (ventral striatum).
58
 The basal ganglia is heavily 
innervated by dopaminergic terminals. Given the role of dopamine in motor function and 
cognition,
60
 it is not surprising that the basal ganglia has numerous pathologies associated with 
DA dysregulation, including Parkinson’s disease, Huntington’s disease, Schizophrenia, and 
Tourette’s syndrome.
37,61–72
 The striatum is the principal component of the basal ganglia and is 
the largest contributor and recipient of the DA system. 
 The striatum consists of the caudate putamen and the nucleus accumbans (Nac). The 
striatum is primarily composed of GABAergic medium spiny neurons (90-95%) that are 
characterized by their dendritic projections covered in “spines”.
58,73,74
 The dopaminergic 
terminals within the striatum originate from two main pathways: the mesolimbic pathway from 
the ventral tegmental area (VTA) and the nigrostriatal pathway from the substantia nigra pars 
compacta (SNc). The description of DA innervation of the striatum is undoubtedly more 
complex than described here and for a more in-depth commentary on this subject in both humans 
and primates, please see Joel and Weiner.
60
  
While there exists no clear neurophysiological differences in these regions, studies have 
identified the role of each region in controlling behavior.
79
 Further, there exists an input gradient 
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throughout the striatum. This gradient is established by two unique dopaminergic inputs to the 
striatum from the mesolimbic pathway, which projects from the ventral tegmental area via A10 
neurons, and nigrostriatal pathway, which projects from the substantia nigra pars compacta via 
A9 neurons.
80
 Differing functionalities have resulted from this gradient. Motor function and 
execution are associated with the dorsal striatum.
75,76,78,81
 The ventral striatum is associated with 
appetitive motivation and reinforcement learning.
77,78,82,83
 In healthy humans and rats, there 




1.5 Measuring DA Release in Brain tissue  
1.5.1 FSCV to Measure DA in Brain Slices 
 FSCV has been extensively used to quantify neurotransmitter release in brain slices 
obtained from rodents.
10,12,14,16,36–38,84,85
 Using FSCV in brain slices for the measurement of DA 
release is one of the principal techniques performed and described in this work. Experimental 
details regarding the harvesting and maintaining of brain slices can be found in the Materials and 
Methods sections of the subsequent chapters. However, to briefly explain, mice or rats are deeply 
anesthetized by a gaseous anesthetic and decapitated. The brain is then immediately removed and 
placed into ice-cold artificial cerebral spinal fluid (aCSF) which, as the name would imply, is a 
solution made to mimic cerebral spinal fluid. This solution contains the salt content, glucose 
necessary to maintain metabolism, and is buffered to a physiological pH. Once the brain is 
sufficiently chilled, 350µm thick coronal brain slices are obtained containing the striatum. 
Harvested brain slices are then transferred to a perfusion chamber where oxygenated aCSF is 




    After the brain slice is allowed to equilibrate for an hour in the perfusion chamber, the 
electrochemical analysis can begin. The procedures for measuring DA release and uptake with 
background-subtracted FSCV has been described previously,
38, 39,86,87
 and will be discussed in 
more detail in the materials and methods sections of the subsequent chapters. Briefly, a pre-
calibrated cylinder carbon-fiber microelectrode is inserted 100µm into the brain slice using 
micromanipulators and a stereoscope. The electrode is positioned between two stimulating 
electrodes in the striatum. An image of a coronal brain slice containing the striatum, the 
stimulating electrodes, and the working electrodes can be seen in Figure 9. In order to evoke DA 
release, a biphasic current is applied to the stimulating electrode to initiate neuronal firing. When 
the neurons undergo exocytosis, DA that diffuses out of the synaptic clefts and comes in contact 






Figure 9. Image of coronal brain slice, stimulating electrodes, and working electrode. The 
working electrode and stimulating electrodes (top) are inserted 100µm into the striatum (shaded 




Brain slice experiments are considered to be ex vivo experiments, providing some of the 
benefits of both in vitro and in vivo experiments. Similar to an in vitro experiment, a researcher 
can easily control the microenvironment of the tissue sample. However using a brain slice allows 
for this environmental control while maintaining significant tissue architecture and neuronal 
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connections that are relevant to the brain in vivo. This conservation of neuronal connection/tissue 
architecture has allowed for pharmacological and genetic manipulations used for in vivo research 




1.5.2 Relevant Pharmacology 
  
 
Figure 10. Structures of amphetamine and α-methyl-p-tyrosine.   
 
 Pharmacological manipulations can be used to elucidate specific mechanisms of 
neurotransmission. In this document two principal drugs were used to study how vesicular 
storage is affected in models of neurotoxicity. The two compounds used for such manipulation in 
this dissertation are amphetamine (1-methyl-2-phenethylamine, AMPH) and α-methyl-p-tyrosine 
(AMPT).  
  Amphetamine (1-methyl-2-phenethylamine, AMPH) is a psychostimulant used to treat 
attention deficit disorder and narcolepsy. It was first developed and tested on animals in the late 
19
th
 and early 20
th
 centuries and was later synthesized in an attempt to develop powerful 
decongestants.
92
 It was the later development in which Alles et. al. reported on its affects as a 
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powerful stimulant. It was not until the 1950s that it was determined that AMPH caused the 
release catecholamines in the CNS.
92
 
   AMPH causes DA release by a few potential mechanisms. Firstly, AMPH can be 
transported from the extracellular space via DAT leading to an AMPH/DA exchange which 
therefore causes the release of DA.
93,94
 However, at high concentrations AMPH, which is 
extremely lipophilic,
95
 readily crosses the plasma membrain of the neuron and releases DA from 
intraneuronal binding which will then be free to undergo release via DAT.
92
 It is this mechanism 
that makes AMPH capable of pharmacologically liberating reserve pool DA.  
 AMPT is a compound that effectively blocks catecholamine synthesis by inhibiting the 
enzyme tyrosine hydroxylase (TH). The conversion of tyrosine to L-DOPA via TH is the first 
and rate limiting step in the synthesis of catecholamines. AMPT has been used clinically to 




1.6 The Summary of the Subsequent Chapters  
 
It was the goal of this introductory chapter to provide information regarding the 
background information on the methodologies used, relevant neuroscience, and relevant 
neuroanatomy that will aid in understanding the recurring themes in the following chapters. The 
subsequent chapters describe three separate projects that represent the amalgamation of my 
research completed throughout my career as a graduate student. The focus of Chapter 2 is how 
DA regulation is altered after chemotherapy treatment. This study was performed to elucidate the 
physiological mechanism of post-chemotherapy cognitive impairment (PCCI). The focus of 
Chapter 3 is to describe regional differences in DA dysregulation in the striatum of transgenic 
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Huntington’s disease model mice. Finally, Chapter 4 describes novel methodology employing 
the use of photoreleasable compounds to aid in neurological research.  
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Chapter 2. The role of DA Regulation in Post-Chemotherapy Cognitive 
Impairment  
 
Alterations in DA release and uptake as a result of chemotherapy treatment in rats is 
discussed in this chapter. The results presented regarding carboplatin-treated rats were recently 
accepted for publication in ACS Chemical Neuroscience.  
2.1 Introduction to PCCI  
 
The use of chemotherapy for the treatment of cancer has proven to be clinically essential. 
Unfortunately, chemotherapeutic treatment approaches, while effective in killing cancer cells, 
are also toxic to other cell populations in the body. This toxicity has been addressed to a certain 
extent and has led to alterations in chemotherapy strageties with the goal of maximizing effective 
treatment while minimizing side effects. Nevertheless, chemotherapy leads to multiple side 
effects that decrease a patients’ quality of life not only during treatment, but also long after the 
treatment has concluded. It has been determined that cells in the central nervous system (CNS) 
are particularly vulnerable to the effects of chemotherapy. This vulnerability applies to both 




Post-chemotherapy cognitive impairment (PCCI), also known as “chemobrain,” is a 
syndrome caused by CNS toxicity as a result of chemotherapy agents.
8
 The term is representative 
of any alterations in cognition as a direct result of chemotherapy treatment.  Improvements in 
cancer treatment and early detection capabilities have made chemobrain more abundant and of 
greater relevance to the medical community. Past studies have revealed that 18% of breast cancer 
patients that receive standard chemotherapy treatment
9
 and 30% of all cancer patients that 
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receive high level chemotherapy treatment experience chemobrain.
10
 Additionally, up to one-
third of females who have undergone chemotherapy treatment for breast cancer report symptoms 
of PCCI.
11
 Various alterations in neurological function that occur with chemobrain include loss 




Although the underlying causes of chemobrain are still unknown, a variety of 
mechanisms have been proposed. One possibility is that the expression of genes that heighten the 
probability of getting cancer may also increase the likelihood for vulnerability to the negative 
side effects of chemotherapy treatment.
14
  These genetic factors include blood brain barrier 
dysfunction, impaired DNA repair mechanisms, and dysregulation of the immune system.
14–18
 It 
has also been proposed that chemotherapy-induced DNA damage can lead to an increase in 
cytokine production that promotes a chronic state of inflammation leading to cognitive 
impairments.
19–22
 Chemobrain may also be caused, in part, by the disruption of blood flow 
throughout the vasculature of the brain. This phenomenon could result in ischemia, which may 
directly affect cognition due to oxidative stress.
23
 Moreover, it has been suggested  that the 
inherent toxicity of many chemotherapeutic agents may impair neurotransmitter signaling.
14
 
Both dividing and non-dividing progenitor cells and oligodendrocytes in the brain have also been 
shown to be highly sensitive to some chemotherapeutics, even more so than the cancer itself.
24
 
Exposure to chemotherapeutics resulting in oligodendrocyte dysfunction could lead to 
downstream effects similar to chemobrain since these cells are responsible for forming myelin 
sheaths.  The destruction or damaging of these cells might slow down the speed of neural 




2.1.1 PCCI and Dopamine  





 and locomotor control.
26
  Alterations in DA system function 
have been observed in response to chemically induced oxidative insult,
27
 genetic modifications 
that model oxidative stress,
28
 and neurodegenerative disease.
27,29–34
 We therefore hypothesized 
that treatment with chemotherapeutic agents would result in alterations in DA release and uptake. 
The identification of such impairments could have important consequences for the cognitive 
processes associated with DA signaling and may imply that other neurotransmitter systems could 
also be affected. 
 Potential treatment to alleviate or prevent chemobrain has supported DA’s potential role 
in the disorder. Psychostimulants have proven to be somewhat successful in symptomatic 
treatment. For example, methylphenidate, a DA uptake inhibitor typically used to treat ADHD, 
has been successfully used to improve cognitive function.
35–37
 Another study performed by Kohli 
et al. involved the treatment of breast cancer patients with modafinil, which is a drug used to 
promote wakefulness and is typically used to treat narcolepsy. This study found that patients who 
received 200mg of modafinil showed a significant improvement in speed memory and attention 
skills in comparison to their placebo controls.
38
 The fact that DA reuptake inhibitors may 
alleviate the cognitive impairments associated with chemobrain supported our hypothesis, 
therefore providing justification to further investigate how DA dysregulation may be implicated 




2.1.2 Animal Models of PCCI 
Few studies addressing chemobrain using animal models have been published. The 
studies that have been done have suggested that the majority of types of chemotherapeutics, 
including DNA cross-linking agents, mitotic inhibitors, antimetabolites, and antihormonal agents  
can lead to a range of cognitive impairments.
39
 There have been animal studies performed whose 
results suggest that cognitive impairments analogous to those found in humans afflicted by PCCI 
occur in animals treated with a variety of chemotherapeutic agents.
40–45
 Some of the cognitive 
tests used in these studies include the Morris water maze, novel location recognition, and non-
matching to sample learning.
43,46
  
 The majority of animal studies investigating chemobrain have been done using rats. A 
study by Mustafa et al. found that 5-fluorouracil (5FU) negatively impacted spatial working 
memory and neuronal proliferation in male Lister-hooded rats.
47
 This study showed that there 
was a decrease in exploratory time after rats were placed in a novel location after a cycle of 5FU 
treatment. Although it was determined that there was no significant difference in proliferating 
cell counts, it was determined that brain-derived neurotrophic factor (BDNF) levels were 
significantly diminished in 5-FU treated rats in comparison to their vehicle-treated controls.
47
  
 Mice have also been used to model chemobrain. A study by Joshi et al. looked into how 
adriamycin (ADR) treatment, a commonly used chemotherapeutic agent, could possibly affect 
the brain through oxidative stress. This was accomplished by measuring glutathione (GSH) 
levels, which is an antioxidant found in the CNS. The study determined that there was 
significantly less GSH in mice treated with ADR in comparison to saline-treated controls.
48
 This 
finding corresponds to an increase in oxidative stress which may contribute to the symptoms 
associated with chemobrain. Further work in mice by Dietrich et al. found that clinically relevant 
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treatment with carmustine (BCNU), cisplatin, and arabinoside led to enhanced neuronal cell 
death both in vitro and in vivo in treated mice.
24
 This study began the process of identifying 
certain cell populations that are specifically vulnerable to chemotherapy-related toxicity. 
Although there are limited animal studies regarding PCCI, the previous work involving cognitive 
testing in chemotherapy-treated rodents and the early physiological studies performed have 
proven that animal models of PCCI are clinically relevant models applicable to the human 
condition.  
 
2.1.3 Chemotherapy Agents Associated with PCCI 
2.1.3.1 Carboplatin 
 
Carboplatin (cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), depicted in 
figure 1, is a chemotherapeutic agent commonly employed in the treatment of various cancers, 
including cancers of the head and neck, breast, ovaries, bladder, and colon.
49–51
 It effectively 
treats cancer by forming interstrand and intrastrand DNA crosslinks that lead to apoptosis and 
cell growth inhibition. Carboplatin has become popular as an alternative to cisplatin, which had 
caused severe side effects during and after treatment.
52
 Despite its advantages over cisplatin, 
carboplatin has been implicated in PCCI and readily crosses the blood brain barrier.
8,53,54
   
 
 Figure 1. Carboplatin structure   
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2.1.3.2 CMF Chemotherapeutic Cocktail  
 
 The cocktail containing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) is 
typically used as a frontline treatment of breast cancer.
55–60
 The modes of action for these drugs 
are a DNA alkylating agent, an anti-folate agent, and a thymidylate synthase inhibitor, 
respectively. CMF is known to disrupt the blood brain barrier and potentially cause 
encephalopathy. The three components of this cocktail can be seen in Figure 2.  
 
 A)                        B) )           C)  
Figure 2. CMF component structures. A) Cyclophosphamide B) Methotrexate C) 5-Fluorouracil  
 
 
2.2 Summary of the Studies Described in this Chapter 
 
The following sections describe the studies performed on DA dysregulation involved in 
chemobrain. These studies involve measuring DA release and uptake with FSCV, HPLC analysis 
of DA metabolites, and behavior measurements. These studies were performed with carboplatin-
treated rats and rats treated with the CMF cocktail.  
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2.3 Materials and Methods 
2.3.1 Animals 
2.3.1.1 Carboplatin Studies  
 
All experiments were carried out in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. All procedures were approved by the 
University of Kansas Institutional Animal Care and Use Committee.  Male Wistar rats (Charles 
River Laboratories, Inc., Wilmington, MA, USA) were housed 3 per cage in the University of 
Kansas Animal Care Unit.  Food and water was available ad libitum. Rats were maintained on a 
12 hour light/dark cycle with lights on at 6:00 AM and lights out at 6:00 PM.  A temperature of 
70 ± 2 °C and humidity level of 50 ± 20% was maintained.   Rats were approximately 9 weeks 
old upon arrival, 10 weeks old at time of first treatment with carboplatin or saline, and 14 weeks 
old at the time of neurochemical analysis by FSCV. 
 
2.3.1.1 CMF Studies  
 
Female Wistar rats (Charles River Laboratories, Inc., Wilmington, MA, USA) were 
housed three per cage with food and water ad libitum in a temperature/humidity-controlled 
environment. Rats were maintained on a 12 hour light/dark cycle with lights on at 6:00 AM and 
lights out at 6:00 PM.  A temperature of 70 ± 2 °C and humidity level of 50 ± 20% was 
maintained. All experiments were carried out in accordance with the National Institutes of 
Health Guide for the Care and Use of Laboratory Animals. All procedures were approved by the 





Carboplatin (lot number C2538), d-amphetamine sulfate (lot number 065K1894), and α-
Methyl-DL-tyrosine methyl ester hydrochloride (lot number 037K1402) were purchased from 
Sigma-Aldrich (St. Louis, MO, USA). AMPH was dissolved in biological saline (0.9% NaCl, 
2.5 mg/mL) prior to use. For all 5-HT and reserve pool DA experiments, pharmaceutical grade 
carboplatin (lot number 61703-339-50) was purchased from Hospira (Lake Forest, IL, USA). 
Cyclophosphamide, methotrexate, and 5-fluorouracil were purchased from Sigma-Aldrich (St. 
Louis, MO, USA). 
 
2.3.3 Electrode fabrication 
Carbon-fiber cylindrical microelectrodes were fabricated as previously described.
27,61
  
Briefly, 7µm carbon-fiber purchased from Goodfellow Cambridge Ltd. (Huntingdon, England) 
was loaded into glass capillaries (4in, 1.2mm OD; A-M Systems, Inc. Carlsborg, WA, USA) and 
pulled using a heated coil puller (Narishige International USA, East Meadow, NY, USA). 
Carbon-fiber tips were then cut with a scalpel 25µm from the end of the glass seal. Electrodes 
were then sealed by dipping into a well-mixed epoxy mixture of  0.24g EPI-CURE 3234 Curing 
Agent (lot FCXC4114/0886GG) and 2.00g EPON Resin 815C (lot HADN0003/1307GG). 
Excess resin was removed by dipping several times in toluene and electrodes were then baked 
for 1 hour at 100°C. The electrodes were back-filled with 0.5 M potassium acetate in order to 




2.3.4 Chemotherapy Treatment  
2.3.4.1 Carboplatin Studies 
 
Male Wistar rats received an injection (iv, tail vein) of carboplatin once a week for four 
consecutive weeks. All carboplatin solutions were made up in biological saline (2.5mg/mL, 
15mg/mL, and 26.6mg/mL) prior to injection. There were 3 experimental groups that included 
treatments with 0.9% biological saline, 5.0mg/kg carboplatin, and 20mg/kg carboplatin. Both 
dosage and treatment regimen were chosen to mimic a reasonable clinical dosing regimens and 
to allow for the drug effects to stabilize.  
To further examine the effect of carboplatin treatment on DA reserve pool, Male Wistar 
rats received one injection (iv. tail vein) of carboplatin once a week for four consecutive weeks. 
For this round of treatment, there were two experimental groups consisting of treatment with 
0.9% biological saline or a 20mg/kg dose of pharmaceutical grade carboplatin (10mg/mL, 
Hospira, Inc).  
 
2.3.4.2 CMF studies 
 
Female Wistar rats received weekly intraperitoneal injections of 0.9% biological saline vehicle 
or a CMF drug mixture of 40mg/kg cyclophosphamide, 37.5mg/kg methotrexate, 75mg/kg 5-
fluorouracil for four weeks. There were two experimental groups that included treatments of 
0.9% biological saline (n=6) and CMF-treated (n=4). Cyclophosphamide, methotrexate, and 5-
fluorouracil were purchased from Sigma-Aldrich (St. Louis, MO, USA). The chemotherapeutic 
rat dosages for the CMF injections were based on previous studies by Briones and Woods.
64




2.3.5 Behavioral Methods 
Throughout carboplatin (or saline control) treatment, locomotor activity was monitored 
as a function of total distance traveled using a force-plate actometer.  The force-plate actometer 
was constructed by Professor S. C. Fowler at the University of Kansas and is described 
elsewhere.
65
 The actometer was located in a sound-attenuated cubicle. The door of the cubicle 
was closed and the room was evacuated when taking measurements to ensure that the animal was 
not disturbed during recording. Each animal was placed in the force plate actometer for 
behavioral analysis for 30 minutes once a week for four consecutive weeks prior to 
chemotherapy administration.  Ambient temperature was held at 70°C during the collection of all 
behavioral recordings.  All behavioral measurements were taken during the rodent light cycle 
between 11:00 AM and 2:00 PM 
 
2.3.6 Brain Slices  
Brain slices were harvested as previously described.
31
 In summary, rats were deeply 
anesthetized by isoflurane inhalation and decapitated. The brain was then immediately removed 
and placed into ice-cold artificial cerebral spinal fluid (aCSF). The aCSF solution contained the 
following concentrations: 2.5 mM KCl, 126 mM NaCl, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.4 
mM CaCl2, 1.2 mM MgCl2, 20 mM HEPES, 11 mM D-glucose. The pH was adjusted to 7.4 with 
NaOH. To ensure the tissue received ample oxygen, the aCSF was continuously bubbled with 
95% O2/5% CO2 throughout the experiment. After chilling for one minute, the cerebellum was 
removed and the brain was bisected longitudinally using a sterile razor blade. The sample was 
then stored at -80°C and saved for HPLC analysis. The other hemisphere of the brain was then 
glued to a plate against a cube of agar for support. Several 300 µm coronal brain slices were then 
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obtained using a vibratome (Leica Microsystems, Bannockburn, IL, USA). In a typical recording 
session, a single striatal brain slice was transferred to a perfusion chamber where oxygenated 
aCSF, maintained at 34 ºC using a thermostatted perfusion chamber and in-line heater, flowed 
over the slice at 2 mL/min. Slices were equilibrated for at least one hour before collecting 
measurements. 
 
2.3.7 Striatal Area Measurements in Carboplatin Treated Rats.   
After tissue harvesting, coronal slices containing the striatum was transferred to a petri 
dish containing aCSF. A glass slide was immediately placed on top of the slide to prevent the 
tissue from curling. The slice was then placed under a stereomicroscope (Nikon SMZ745, 
Japan). Brain slices were imaged by an eyepiece camera (AmScope MU300, Irvine, CA) 
mounted on the stereomicroscope. The striatum was selected and outlined (Figure 7) using 
Photoshop CS6 (Adobe, San Jose, CA). The area of the striatum in pixels was determined and 
converted to cm
2
 via calibration (See Figure 7).  
 
2.3.8 Electrochemical Measurements  
2.3.8.1 Single Pulse Measurements  
 
Procedures for measuring DA release and uptake with background-subtracted FSCV have 
been described in detail previously.
30, 31,63,66
 Briefly, a pre-calibrated cylinder carbon-fiber 
microelectrode was inserted 100µm into the brain slice using micromanipulators and a 
stereoscope. The electrode was positioned between two biphasic stimulating electrodes (A-M 
Systems Inc, Carlsborg, WA, USA) in the striatum. For DA detection, a triangular waveform 
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starting at -0.4V, scanning up to 1.0V, and back to -0.4V vs an Ag/AgCl reference electrode, was 
applied to the carbon-fiber microelectrode at a scan rate of 300V/s and an update rate of 10 Hz. 
Dopamine release was evoked by applying a single, biphasic current pulse (current of 350 µA, 4 
ms total duration) to the stimulating electrode. The peak current after stimulation was used for all 
release measurements. The current measured from DA oxidation was plotted versus potential and 
the successive voltammograms were plotted versus time. To account for the natural 
heterogeneity of DA release in the striatum, measurements were taken in four different regions 
of the striatum four times. 
 
2.3.8.2 Reserve pool DA Measurements in Carboplatin-Treated Rats   
 
In order to monitor reserve pool DA efflux, single pulse measurements were taken every 
five minutes while treating the brain slice with alpha methyl p tyrosine (αMPT). These 
measurements were taken until stimulated DA release was completely diminished. At this point 
the brain slice was perfused with 20µM amphetamine (AMPH) and 50µM αMPT. DA release 
was then continuously measured for 25 minutes without electrical stimulation. 
 
2.3.8.3 Multiple Pulse Measurements in CMF-Treated Rats   
 
After measuring the four quadrants of the caudate-putamen four times, DA efflux was 
evaluated under electrical stimulated DA efflux. To evaluate DA efflux, electrical stimulation 
pulses of either 1, 2, 4, 6, 8, or 10 times within the 15 second file durations were done within the 
caudatelateral quadrant of the caudate-putamen region. Slices were allowed to equilibrate for 5 
minutes between sample recordings. 
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2.3.9 Modeling Stimulated Release  
Dopamine release and uptake kinetics were analyzed using modeling software written by 
the R.M. Wightman group (University of North Carolina, Chapel Hill, NC, USA). This modeling 
software was used to measure dopamine per pulse ([DA]p), which is dopamine release per 
electrical stimulus corrected for electrode performance and uptake, and Vmax, which is the 
maximum rate of dopamine uptake. The time of stimulation is loaded into the software; however, 
the actual rise in the DA oxidation current typically does not occur immediately after 
stimulation. This delay, which may be on the order of 100 ms, is influenced by several factors, 
including the time it takes for DA to diffuse to the electroactive surface and adsorption of DA to 
the electrode surface. The mechanism of DA reuptake has been well-defined previously.
29
 
Briefly, DA uptake obeys Michaelis-Menten kinetics
67–69
under the following reaction paradigm:   
(𝐷𝐴)𝑜 + 𝑇 ↔ (𝐷𝐴)𝑇 →  (𝐷𝐴)𝑖 + 𝑇 
where extracellular dopamine, (DA)o, is converted to intracellular dopamine, (DA)i. T represents 










where [DA] represents the extracellular concentration of DA in the brain, [DA]p is the change in 
[DA] at the electrode surface in response to each electrical stimulus pulse, and Vmax and KM are 
constants in the Michaelis-Menten equation that described how the transporter functions.
70  
A KM 
value of 0.2 µM was used during the modeling operation. The parameters Vmax and [DA]p were 




2.3.10 Striatal Dopamine Content 
Striatal tissue samples were stored at -80 °C until use. Samples were homogenized in 0.1 
M perchloric acid and centrifuged at 7200g for 10 minutes. Same day dopamine tissue content 
was determined using HPLC coupled with electrochemical detection. The supernatant was 
manually injected onto a Phenomenex Luna 2.5u C18(2)-HST column (100 x 3.00 mm) for 
separation followed by detection using an ESA 5014B microdialysis cell (E1 = -150 mV; E2 = 
+230 mV). A guard cell (ESA 5020) was used in-line before injection loop and was set at +350 
mV. The mobile phase was delivered at a flow rate of 0.38 mL/min by a Shimadzu LC-20AD 
HPLC pump (Shimadzu Scientific Instruments, Columbia, MD). Mobile phase composition: 
75.18 mM sodium phosphate (monobasic, monohydrate), 1.387 mM 1-octanesulfonic acid 
(sodium salt, anhydrous), 0.125 mM ethylene diamine tetraacetic acid, 0.0025 % triethylamine, 
and 10 % acetonitrile; pH 3.0 adjusted with 85% phosphoric acid. Dopamine peak area was 
integrated and quantified against known standards using LC Solutions Shimadzu Software. 
Dopamine concentrations were normalized to total protein levels as determined (in duplicate) by 
the commercially available BCA™ protein assay kit from Thermo Scientific (Thermo Fisher 





 Statistical analyses were conducted using GraphPad Prism software (GraphPad Software 
Inc., San Diego, CA, USA).  For statistical analyses, n = the number of rats.  Data are given as 
mean ± SEM. 
 
2.4 Carboplatin Results and Discussion 
 
Impairments in the release of DA, 5-HT, Glutamate, GABA and other neurotransmitters 
could be detrimental to many neurological functions, including cognition, mood, and the control 
of movement. Clinical studies have suggested that DA may play a role in chemobrain.
71,72
 
Additionally, non-clinical research implies the involvement of DA impairment in 
chemobrain.
14,43,72–75
 It has been well-established that dopaminergic function in the basal ganglia 
is important in cognition.
26,76–81
 Therefore, we investigated the release and uptake properties of 
DA, which is readily measured electrochemically with FSCV.  
Electrically-stimulated DA release and uptake was quantified in the four quadrants of the 
striatum of rat brain slices. The dorsal striatum is associated with motivation and reward and 
motor function,
82,83
 whereas the ventral striatum is associated with reinforcement learning.
84
 
Measurements were taken in the four quadrants to account for potential regional differences of 
release, which are known to have a dorsal to ventral gradient in multiple rodent species and non-
human primates.
85
 It was determined that DA release was diminished among all quadrants, and 
also that uptake is decreased. DA content, measured by HPLC, and the DA reserve pool, assayed 
by electrochemical measurement of AMPH-induced efflux, were unaffected by carboplatin 
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treatment. These results suggest that this treatment impairs the ability of terminals to function 




Figure 3. Dopamine release comparison of a saline-injected control rat and a highest dose 
carboplatin-injected rat. Representative color plots and stimulated DA release plots, sampled 
along the horizontal dashed lines on the color plots, are shown.  Cyclic voltammograms, sampled 
along the vertical dashed lines on the color plots, are shown directly above the stimulated release 




2.4.1 Striatal Dopamine Release 
Electrically stimulated DA release in the dorsal lateral (DL), dorsal medial (DM), ventral 
medial (VM), and ventral lateral (VL) quadrants of the striatum was measured with FSCV in 
coronal brain slices. Four measurements were taken at random locations within each quadrant 
and averaged. Representative data for 0 mg/kg and 20 mg/kg carboplatin treatment groups are 
shown in Fig. 3. The representative cyclic voltammograms confirm that the analyte measured is 
DA. Each color plot consists of a series of unfolded, stacked cyclic voltammograms.  The current 
response is color-coded.  The absence of faradaic currents, other than those due to DA oxidation 
and reduction, suggest that no electroactive species are released in response to electrical 





Figure 4. A) Image of a coronal brain slice with labeled quadrants of the striatum. B) 
Representative stimulated DA release plots for each dose taken from the DL quadrant of the 
striatum. The cyclic voltammograms acquired at the point of maximum DA oxidation are located 
above the corresponding release plots. C) [DA]max at each dose shown in each of the four regions 
of the striatum (two-way ANOVA: main region effect, p = 0.5288; main dose effect, p < 0.001; 
0, 5, 20 mg/kg, n = 5).). D) [DA]max averaged across all brain regions at each dose (one-way 
ANOVA: main dose effect, p < 0.001; 0, 5, 20 mg/kg, n = 5).  
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Representative stimulated release plots (current versus time) for each treatment group, 
collected from striata, are shown in Fig. 4B. The presence of DA was confirmed by the cyclic 
voltammograms sampled at the point of peak release on each plot. The data reveal a statistically 
significant carboplatin treatment effect on DA release in the striatum: 71.5% of vehicle control at 
5 mg/kg and 40.6% at 20 mg/kg. (Fig. 4C; two-way ANOVA main dose effect, p < 0.001; Fig 
4D; one-way ANOVA: main dose effect, p < 0.001; 0, 5, 20 mg/kg, n = 5). However, there was 
no significant effect of region on stimulated DA release (Fig. 4C; two-way ANOVA, p = 0.5288, 
F3,52 = 0.7474, number of rats: 0, 5, 20 mg/kg, n = 5). The attenuation of DA release was, 
therefore, found to be generalized throughout the entire striatum.  A bar graph of [DA]max values 
averaged across the four quadrants (Fig 4A) is shown in Fig. 4D. Since DA is involved in motor 
function and cognition,
25
 it is possible that the symptoms of chemobrain—such as short term 
memory loss and fatigue—could be influenced by a generalized depression of the release of 
dopamine into the striatal synapses for chemotherapy treated patients.
26,86,87
  However, the 
suppression of other neuronal populations, including GABAergic neurons and glutamatergic 





Figure 5. Dopamine release and uptake is attenuated in carboplatin treated rats compared to 
saline controls.  A) Representative example of a fitting curve used for modeling.  The arrow 
indicates the point of stimulation.  B) [DA]p measured from each dosing group in each region. 
No regional differences in the striatum were found, but generalized release was sharply 
attenuated (two-way ANOVA: main region effect, p = 0.4430, 0, 5, 20 mg/kg, n = 5; main dose 
effect, p < 0.001; 0, 5, 20 mg/kg, n = 5). C) [DA]p averaged across all brain regions at each dose 
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(one-way ANOVA: main dose effect, p = 0.0011; 0, 5, 20 mg/kg, n = 5)  D) Vmax measured from 
each dosing group in each region. No significant difference of Vmax was found between regions 
(two-way ANOVA: main region effect, p = 0.3836, 0, 5, 20 mg/kg, n = 5; main dose effect, p < 
0.001; 0, 5, 20 mg/kg, n = 5). E) Vmax averaged across all brain regions at each dose (one-way 
ANOVA: main dose effect, p < 0.001; 0, 5, 20 mg/kg, n = 5)  
 
2.4.2 Determination of [DA]p and Vmax 
 In order to quantify DA uptake in carboplatin-treated rats, the stimulated release plots 
were modeled.  This modeling process allowed the determination of Vmax, the maximum rate of 
DA uptake, and [DA]p, DA release per electrical stimulus pulse.  The determination of [DA]p 
corrects for electrode performance and DA uptake by the dopamine transporter.  This modeling 
process is described in Materials and Methods, and a representative modeled stimulated release 
plot is shown in Fig. 5A. A statistically significant attenuation in [DA]p was found across all 
regions of the striatum after four weeks of carboplatin treatment: 80.0% of saline control at 5 
mg/kg and 57.7% at 20 mg/kg (Fig. 5B; two-way ANOVA main dose effect; p < 0.001; Fig 3C; 
one-way ANOVA: main dose effect, p = 0.0011; 0, 5, 20 mg/kg, n = 5). Similar to the 
uncorrected release data in which [DA]max was determined, no significant effect was found 
between the four regions of the striatum probed (two-way ANOVA main region effect, p = 
0.4430; 0, 5, 20 mg/kg, n = 5). Additionally, a substantial effect of carboplatin dose on Vmax (Fig. 
3D and 3E), the maximum rate of DA uptake by the membrane-bound dopamine transporter 
protein molecules, was found: 54.9% of saline control at 5 mg/kg and 56.8% at 20 mg/kg (two-
way ANOVA main dose effect, p < 0.001; Fig 5E; one-way ANOVA: main dose effect, p < 
0.001; 0, 5, 20 mg/kg, n = 5). However, similar to the [DA]p data, there was also no statistical 
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difference in Vmax between the regions of the striatum sampled (two-way ANOVA main region 
effect, p = 0.3836, 5, 20 mg/kg, n = 5). To illustrate the overall effect of carboplatin treatment on 
striatal DA release within the striatum, graphical representations of [DA]p and Vmax are shown in 
Figs 5C and 5E, respectively, with these values averaged across the four quadrants. 
 These data show that DA per pulse, as well as DA uptake, is diminished in carboplatin-
treated rats. This finding suggests that the decrease in stimulated DA release that occurred in 
response to electrical stimulation did not arise from enhanced DA clearance, given the 
competitive relationship between DA release and uptake, by the dopamine transport system.  
According to Michaelis-Menten enzyme kinetics, Vmax is directly proportional to the total 
number of functioning dopamine transporter protein molecules.
70
 Therefore, it is possible that the 
total number of functioning dopaminergic terminals decreases with carboplatin treatment—a 
finding that is not surprising given the inherent toxicity of carboplatin.  It is important, however, 
to obtain measures of how much DA is present within the terminals since this parameter would 
be a direct measure of how much DA is available for release.  
   
2.4.3 Dopamine Reserve Pool Content  
The generalized three-pool model of neurotransmitter-containing vesicles within neurons 
consists of a readily releasable pool, a recycling pool, and a reserve pool.
88–90
  The readily 
releasable pool contains only 1-2% of vesicles within a neuron.
90
 In the context of our 
voltammetric recordings, DA from the readily releasable pool in striatal slices would be released 
and detected by FSCV upon application of a single electrical stimulus pulse.  After depleting the 
readily releasable pool vesicles, they are replenished by the recycling pool, which accounts for 5-
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20% of the total number of vesicles within the neuron.
91–93
 The reserve pool contains 80-90% of 
the total number of vesicles within a neuron and is thought to be mobilized in response to 






Figure 6. Quantitation of reserve pool DA.  The brain slice was continuously exposed αMPT, a 
tyrosine hydroxylase inhibitor, in order to block DA synthesis. Electrically evoked DA release 
was measured every five minutes until the signal diminished (occurring at 150 minutes in the 
data shown). Traces are shown here every 30 minutes for clarity. The addition of AMPH then 
caused the efflux of reserve pool DA.  The cyclic voltammogram confirms the presence of DA at 




Experimentally, reserve pool DA can be mobilized by intense electrical 
stimulation
28,30,93–95
 or pharmacological manipulation.
30,95
 Here, we isolated reserve pool DA in 
striatal brain slices by blocking DA synthesis with αMPT while applying single-pulse electrical 
stimulations every five minutes (Fig. 6).
30
  The compound αMPT inhibits DA production by 
blocking tyrosine hydroxylase, the rate-limiting enzyme in DA synthesis.
96
  When αMPT was 
present in the perfusion buffer, the DA signal dissipated in response to stimulation, leaving only 
reserve pool DA within the terminals. Subsequent application of AMPH and αMPT together 
resulted in the spontaneous, quantifiable efflux of this reserve pool DA.  The concentration of 
DA measured as a result of this treatment was 2.59 ± 0.53 µM in slices from control rats and 
2.45 ± 0.63 µM in slices from 20 mg/kg carboplatin-treated rats.  There was no significant 
difference in DA efflux (unpaired t-test, p > 0.05, n = 6 control rats and 5 rats treated with 20 
mg/kg carboplatin), suggesting that the mechanism leading to stimulated DA attenuation in the 
striatum is not based on storage impairment.  
 
2.4.4 Striatal Dopamine Content 
Homogenized striatal tissue samples were analyzed by high performance liquid 
chromatography (HPLC) with electrochemical detection in order to measure the total content of 
DA and DOPAC (Table 1).  Although there appears to be a trend, we found no significant dose 
effect on DA content (one-way ANOVA, p = 0.81; 0, 5, and 20 mg/kg, n = 5), DOPAC content 
(one-way ANOVA, p = 0.87; 0, 5, and 20, n = 5), or DA/DOPAC (one-way ANOVA, p = 0.39; 
0, 5, and 20mg/kg, n = 5) in homogenized striatal samples from vehicle- and carboplatin-treated 
rats. Several conclusions can be drawn from these data.  First, since DOPAC levels, as well as 
the DA/DOPAC ratio, did not change with carboplatin treatment, it is unlikely that the 
62 
 
metabolism of DA to DOPAC is altered by this treatment.  Second, these results agree with the 
reserve pool efflux results; thus, DA is present in proper amounts in carboplatin treated rats, but 
it is not released efficiently.   
 
Table 1: Total DA and DOPAC content and DA/DOPAC ratio from homogenized striatal 
lysates.  The number of rats analyzed (n) is indicated in parentheses.  
 DA DOPAC DA/DOPAC 
 µg DA / mg protein µg DOPAC / mg 
protein 
 
0 mg/kg (n=5) 1.15 ± 0.29 0.31 ± 0.09 4.12 ± 0.53 
5 mg/kg (n=5) 1.10 ± 0.27 0.30 ± 0.09 3.59 ± 0.63 
20 mg/kg 
(n=5) 





2.4.5 Striatal area measurements in carboplatin treated rats  
 Visible neurodegeneration of the striatum is hallmark to certain neurodegenerative 
diseases and toxic events.
97–100
 In order to see if carboplatin treatment lead to visible striatal 
degeneration, striatal area measurements were made. A representative image of a coronal brain 
slice with the striatum shaded in can be seen in Fig 7. After analyzing the striatal areas of 
carboplatin-treated rats (n = 5) and saline-treated controls (n = 6) it was determined that there is 
no significant visible striatal loss after carboplatin treatment (unpaired t-test, p > 0.05, n = 6 
control rats and n = 5 rats treated with 20 mg/kg carboplatin). Along with the content data and 
since the striatal area was not altered by carboplatin treatment, it is not likely that the striatum 
has undergone a significant amount of atrophy; thus, the decrease in release is likely not due to 
extensive damage of the neurons themselves.   
 
 
Figure 7. Striatal area was unaffected in rats treated with carboplatin. (unpaired t-test, p > 0.05, 
n = 6 control rats and n = 5 rats treated with 20 mg/kg carboplatin) 
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2.4.6 Behavioral Measurements.  
Throughout their four weeks of carboplatin treatment, rats were subjected to behavioral 
analysis. To study the effects of carboplatin treatment on locomotion, animals were placed in a 
force-plate actometer to determine if carboplatin treatment decreased the natural tendency to 
explore when placed in the new environment of the force-plate recording chamber. Throughout 
carboplatin treatment, the subjects expressed a significant decline in locomotion as measured by 
total distance traveled (Fig. 8). Additionally, the magnitude of decline correlated with the 
number of doses administered (two-way ANOVA: time effect, p = 0.0001; n = 3 per week per 
dose).  
Although there was a significant time affect, there was not a significant treatment effect 
throughout the 4 week treatment period (two-way ANOVA: treatment effect, p = 0.36, n = 3 per 
week per dose).  Because the distance traveled of the vehicle-treated control rats did not decrease 
with increasing time of treatment, while the distance traveled of rats treated with 5 and 20 mg/kg 
carboplatin did decrease, the time effect is not likely caused by habituation (for example, 0 
mg/kg, p > 0.05, n=5; 5 mg/kg p < 0.05, n=5; 20 mg/kg, p < 0.001, Bonferroni post-hoc test, 
Week 1 versus Week 4, statistical tests for other pairings provided in Table 6, Supplementary 
Information). Upon analyzing each treatment group separately, it was found that there was a 
significant decline in locomotor activity for the 20mg/kg dosage group over the 4 week treatment 
period (one-way repeated measures ANOVA, p < 0.01; n=3). It is possible that other 
physiological factors associated with carboplatin treatment could impede locomotor activity; 
nevertheless, since DA plays a significant role in motor function,
26
 it is likely that inhibition of 
DA release would contribute to a decrease in locomotion.  In fact, previous studies have 





  Therefore, our results collectively suggest that the decreased ability of 
carboplatin-treated rats to release striatal DA contributes to this behavioral suppression. 
 
 
Figure 8. Locomotor activity was measured using a force-plate actometer.  Total distance 
traveled was attenuated and a significant time effect was found (two-way ANOVA: time effect, p 
< 0.0001; n = 3 per week per dosage, dose effect, p = 0.3490). There was a significant decline in 
locomotor activity for the 20mg/kg treatment group over the 4 week treatment period (one-way 




2.5 CMF Results and Discussion  
 
2.5.1 CMF Peak Stimulated DA Release in the Striatum 
 
Figure 9. Maximum electrically-evoked DA release separated by striatal region (left) and with 
all regions combined (right).  Striatal DA release is attenuated across all regions (p=0.0001, 2-
way ANOVA, n = 4). 
   
 DA release measurements were also taken in rats treated with the clinically relevant 
chemotherapeutic cocktail, CMF. Electrically-evoked DA release in the dorsal lateral (DL), 
dorsal medial (DM), ventral medial (VM), and ventral lateral (VL) quadrants of the striatum was 
measured with FSCV in coronal brain slices. Four single pulse measurements were taken in each 
quadrant and averaged. DA release in the CMF-treated rats revealed a significant dose affect 
attenuation in all regions of the striatum: 31% of vehicle control (Fig 9; 2-way ANOVA, 
67 
 
p=0.0001, n = 4). Concurrent with the results obtained in carboplatin-treated rats there were no 
regional differences in DA release attenuation (Fig. 9; 2-way ANOVA, p > 0.05, n = 4). The 
attenuation of DA release was, therefore, found to be generalized throughout the entire striatum.   
 
2.5.2 Multiple pulse study  
  
Figure 10. Maximum DA release vs number of stimulus pulses applied. Although DA release is 
attenuated in CMF-treated rats (p < 0.01, 2-way ANOVA, n = 4), there were no statistically 
significant differences in DA release at different numbers of pulses (p > 0.05, 1-way ANOVA). 
To further elucidate the impact of CMF treatment on regional DA release in the striatum, 
we chose to measure DA release under prolonged electrical stimulation, which can lead to 
reserve pool mobilization.
28,30,93–95
 Neurons were increasingly stressed by increasing the number 
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of pulses applied. Measurements were taken in the DL striatum and the number of pulses were 
applied from lowest to highest. Varying the number of pulses can shed light on any differences 
in neuronal sensitivity to prolonged stimulation. As seen in Figure 9, there is significant decline 
in DA release post-CMF treatment (p < 0.01, 2-way ANOVA, n = 4) and this attenuation is 
independent of the number of stimulus pulses applied (Fig. 10; p > 0.05, 1-way ANOVA). 
Similar to the carboplatin study, CMF treatment severely attenuates striatal DA release. This 
attenuation is also generalized across all regions of the striatum, suggesting that the CMF 
treatments affected the striatum in a similar manner as carboplatin. These data suggest that DA 
dysregulation is not a carboplatin-specific phenomenon and has implications to other 
chemotherapy treatment regimes.   
 
2.6 Conclusions  
 
The neurochemical analyses of rats treated with the carboplatin and CMF were performed 
to possibly uncover the underlying mechanisms of PCCI. In both studies, it was found that 
chemotherapy treatment led to an attenuation in DA release in the striatum of treated rats. This 
attenuation was generalized throughout the striatum. Although DA release was attenuated, DA 
content and striatal area remain unaffected after chemotherapy treatment. Reserve pool DA was 
measured in carboplatin-treated rats to determine if chemotherapy treatment altered vesicular 
storage, and it was determined that reserve pool DA storage and mobilization is unaffected after 
treatment. This suggests that DA release attenuation is not simply the result of massive 
neurodegeneration but is actually an impairment in the mechanism of release. Since DA is 
involved in motor function and cognition,
25
 it is possible that the symptoms of chemobrain, such 
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as short term memory loss and fatigue, could be influenced by a generalized depression of the 
release of dopamine into the striatal synapses for chemotherapy treated patients. However, the 
suppression of other neuronal populations, including those containing GABA, glutamate, and 
serotonin, cannot be ruled out. The data presented here may therefore provide insight, and 
possible points of intervention leading to possible therapeutics alleviating or eliminating the 
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Chapter 3. Electrochemical measurements in R6/2 Huntington’s Disease 
Model Mice 
 
3.1 Introduction  
 
Huntington’s disease (HD) is a fatal, autosomal dominant neurodegenerative disorder that 
is characterized by motor dysfunction, altered behavior, and cognitive impairment. HD is caused 
by a CAG repeat expansion on chromosome 4 of the IT15 gene, which encodes the huntingtin 
protein (htt).
1
 An average person normally has 16 to 20 CAG repeats on the huntingtin gene 
while a person with HD will have 40 or more.
2
 This protein is ubiquitously expressed and is 
highly concentrated in the central nervous system (CNS).
3
 The mutation results in a 
polyglutamine (polyQ) expansion near the N-terminus of htt. HD affects 4 to 10 out of 100,000 
people of western European descent and 0.4 out of 100,000 people of Asian descent 
4
. Symptom 
onset for HD typically occurs between 35 and 50 years of age and the age of onset is directly 
correlated to the length of the expanded CAG repeat.
2,5–7
 With an extremely long CAG repeat 
typically of 52 or more, symptomatic onset may begin in juveniles.
5,6,8
 This early onset most 
often also includes a more rapid progression of the disease and increased severity.
2
  
Documentation of the existence of HD can be found as early as the mid-14
th
 century.  
Although little was known about the cause of the disease, it was described as an epidemic of 
what was called “a dancing mania”.
9
  It was not until later that the term “chorea” was used by the 
famed student of all sciences, Paracelsus (more specifically, Philippus Aureolus Theophrastus 
Bombastus von Hohenheim) in the late 15
th




  This term, which is 
derived from the Greek word for “dance,” was used to describe the involuntary muscle 
movements that result from the disorder. HD eventually spread to the new world in the early 17
th
 
century. In the American colonies, HD was coined as “San Vitus” or “That disorder”.
9
 Due to the 
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uncontrollable, unusually rhythmic movements associated with HD, people with the disorder 
were often observed by the top physicians and were misdiagnosed with demonic possession. This 
diagnosis was tragic as the appropriate cure at the time was public execution. It is assumed that 
at least one of the victims of the Salem witch trials was burned at the stake because she suffered 
from HD.
9
 Despite a few previous attempts, an accurate medical description of HD was 
unavailable until 1872 when Dr. George Huntington published his findings in the Medical and 
Surgical Reporter of Philadelphia.
10
 Hence, the disease was named after the young doctor. It is 
interesting to note that this was one of only two publications he would ever write. 
The progression of HD typically occurs over the course of 15 to 20 years from the time of 
initial clinical diagnosis to death.
1
 During the early stages, a slow deterioration in intellectual 
capabilities and minor emotional changes occur.
11
 Other symptoms may include weight loss, 
interruptions in the patient’s sleep cycle, or changes in sexual behavior, and may be caused by 
hypothalamic dysfunction.
12
 Furthermore, patients may begin to exhibit minor motor 
abnormalities such as restlessness, abnormal eye movements, and unusual hand movements.
13
 As 
the syndrome associated with HD progresses, motor function deficits gradually worsen. The 
clinical diagnosis of HD is most commonly based on the development of chorea, which is 




The severity of this phenotypical response to HD ranges from excessive fidgeting and 
exaggerated gesture to severely violent, disabling movements.
11,14
 In the later stages of HD, 
chorea is often replaced with other, more severe movement abnormalities such as bradykinesia, 
dystonia, rigidity, and complete loss of coordination.
13,15
 Eventually, patients with HD lose their 
ability to support themselves. Reasons for this loss of independence include the complete loss of 
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mobility and ability to communicate.  Due to its progressive nature, the effects of late stage HD 
are ultimately fatal. Death can be caused by physical injuries (falling), malnutrition, choking, and 
most commonly, pneumonia.
16
 Along with the physical abnormalities and cognitive impairments 
discussed, HD is also characterized by psychiatric manifestations that may include aggression, 
anxiety, depression, and the initiation or progression of addictive behaviors.  The progression of 
such psychiatric changes can often lead to necessary institutionalization and/or an increase in 
suicidal thoughts and action.
11,17
 The observance of motor function impairments in conjunction 
with these psychiatric and behavior abnormalities can be used to diagnose HD. Additionally, due 
to its autosomal dominant pattern of inheritance, information regarding familial history has also 
been used to diagnose HD. Nevertheless, definitive HD diagnosis can only be confirmed by 
genetic testing. The development of DNA diagnostics has made it possible to properly diagnose 
HD without obtaining standard clinical information.
11
 Despite the available information 
regarding pathology, the underlying mechanism leading to neuronal degeneration is not well 
understood.  HD, therefore, remains incurable and much effort has been and is currently focused 
on understanding the mechanisms of neuronal degradation.  
 
3.1.2 Mechanism of HD 
The striatum, a brain region richly innervated with dopamine-releasing terminals, 
undergoes extensive atrophy throughout the course of HD.  About 90 to 95% of the neuronal cell 
bodies in the striatum are GABAergic medium spiny neurons, which receive input from 
dopaminergic neurons that project from the substantia nigra pars compacta (SNc).  These 
GABAergic neurons project to the pallidum through two distinct pathways: the direct pathway, 
which provides inhibitory tone to the globus pallidus internal segment (GPi), and the indirect 
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pathway, which provides inhibitory tone to the globus pallidus external segment (GPe).  
Activation of the direct pathway facilitates movement, while activation of the indirect pathway 
inhibits movement.  Previous evidence has indicated that the indirect pathway neurons are most 
vulnerable to degeneration as HD progresses; thus, the loss of this pathway results in the 
expression of excess movement in the form of chorea, the hallmark motor feature of HD.
18
 
The mechanisms that underlie the degeneration of these striatal medium spiny neurons 
have been extensively investigated.  It has been shown that mutant htt forms insoluble aggregates 
and nuclear inclusions in medium spiny neurons of patients with HD.
19–21
  The role of aggregates 
in the pathology of HD is considered to be of key importance as their presence suggests that 
mutant htt is processed differently in those afflicted with HD.  Additionally, mutant htt acts to 
impede the function of normal huntingtin protein, which is essential to the viability to the 
neuronal populations that degenerate in HD.
22
  However, it is thought that the toxicity of mutant 
htt itself, a direct result of the polyQ extension, contributes to the majority of the disease 
pathogenesis.
23,24
  This toxicity appears to be enhanced by a mechanism that involves the 




3.1.3 HD Model Rodents 
Since the discovery of the causative mutation of HD, numerous genetically-engineered 
animal models of HD have been developed.  The R6 line of HD model mice were created using a 
1.9 kb gene fragment containing promoter sequences and exon 1 of the mutant human HD gene. 
24
 Among the most commonly used models are R6/1 and R6/2 mice, which possess CAG repeat 
lengths of about 115 and 144, respectively.  Both models only express exon 1 of the 67 exon 
gene. This exon encodes only 3% of the N-terminal region of the protein, suggesting that the 
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expanded polyQ tract responsible for the disease.
26
 As would be expected, the longer repeat 
length is associated with the expression of a more quickly progressing motor phenotype in mice: 
R6/1 mice express overt motor symptoms at 15-21 weeks of age while R6/2 mice express 
symptoms at 9-11 weeks.   
There have since been other genetic HD mouse lines that include larger portions of the 
gene. For example, yeast artificial chromosome (YAC) lines contain between 18 to 128 CAG 
repeats on the whole gene have been reported.
27
 Of these lines, YAC 128 mice have used most 
extensively because they experience progressive neurodegeneration and motor impairments.
9,28,29
 
Unlike the R6 mice, YAC mice tend to live normal lifespans.  For a good review on the 
development of genetic HD model mice, see Levine et al.
30
  
In an attempt to accommodate the need for more complex experiments and to recapitulate 
the neurological HD syndrome more faithfully, von Hörsten et al. (2003) developed a transgenic 
HD model rat (HDtg).  Like the R6/2 mouse, the HDtg rat possesses a truncated portion of the 
gene encoding huntingtin, except that the CAG repeat length is significantly shorter: 51 in the rat 
versus 144 in the R6/2 mouse.  Therefore, it is not surprising that the overt motor behavioral 
phenotype is expressed more gradually by HDtg rats compared to R6/2 mice.  In HDtg rats there 
are no detectable behavioral abnormalities at 5 months of age.  Spatial and working memory 
abnormalities appear at 10 months and coordination loss becomes relevant between 10-15 
months of age. Noticeable striatal atrophy occurs at 12 months of age. 
The studies involved in this chapter were performed using R6/2 HD model mice. The 
R6/2 model is considered to be the gold standard for researchers studying HD since they have 




3.1.4 Past Microdialysis studies 
Microdialysis studies aimed at understanding neurotransmitter alterations in HD model 
mice have been conducted by other groups.  Several features make microdialysis an attractive 
method for measuring neurotransmitter levels in the brain. First, it allows the sampling of 
virtually any chemical species, including small molecule neurotransmitters and neuropeptides, 
that will diffuse into the probe. Furthermore, microdialysis allows the real time, continuous 
sampling of endogenous biological compounds in vivo.  Moreover, the concentrations of a 
specific analyte or set of analytes can be measured over long periods of time.  Sampling times 
can range from minutes to days and perhaps even weeks depending on the probe and its 
surrounding environment. This ability is quite attractive for studying analyte concentration 
changes that may occur over long periods of time. However, most commercially available 
microdialysis probes are large (about 200µm) compared to carbon-fiber microelectrodes used in 
our work (7µm), resulting in the potential for additional tissue damage upon implantation 
31
. This 
damage may influence detected neurotransmitter release.
32
 Moreover, sampling intervals for 
many molecules tend to be on the order of minutes or hours,
33,34
 limiting temporal resolution.   
In one of the first studies aimed at quantifying DA levels in transgenic HD model mice, Petersén 
et al.
35
 found that extracellular DA levels were diminished in 16-week-old R6/1 mice in 
comparison to age-matched WT control mice.
35
  Moreover, even though these extracellular DA 
levels were decreased, post mortem tissue content studies showed no significant difference in 
total DA levels between R6/1 and wild type controls.
35
  Further studies, in which malonate was 
locally applied in vivo by infusion through microdialysis probes, were then conducted.  Malonate 
is a mitochondrial complex II inhibitor that induces DA release and ultimately neuronal cell 
death.
35,36
  Malonate-induced increases of extracellular DA levels were significantly less in R6/1 
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mice compared to WT control mice.  Conversely, increases in extracellular glutamate, aspartate, 
and GABA were not substantially different.   
More recent in vivo microdialysis studies carried out in R6/2 and YAC128 mice have 
reaffirmed and expanded on the results obtained by Petersén et al. in R6/1 mice, demonstrating 
that extracellular DA concentrations were diminished in R6/2 mice and YAC128 mice.
37
 Taken 
together, these microdialysis studies revealed that decreases of extracellular DA are not simply 
due to the loss of neuronal populations or the inability to synthesize DA, but rather that the 
ability of neurons to release DA is impaired.
35,38
 In order to probe the underlying mechanisms 
responsible for decreased striatal DA release, we applied fast-scan cyclic voltammetry at carbon-
fiber microelectrodes to measure sub-second DA release events both in vivo and in brain slices, 
described in subsequent sections of this chapter. 
 
3.1.5 Voltammetric measurements of dopamine release and uptake in R6/2 and R6/1 mice 
Previous behavioral studies have demonstrated that, compared to WT controls, R6/2 mice 
have a blunted locomotor response to cocaine (COC) and methamphetamine (METH), inhibitors 
of DA uptake, suggesting an impairment of DA release.
8,38
 These behavioral studies, taken with 
the microdialysis results of Petersen et al. (2002), prompted us to investigate how mechanisms of 
DA release and uptake are impacted in HD model rodents.  Initially, DA release and uptake was 
measured using FSCV in striatal slices acutely harvested from R6/2 mice and age-matched wild 
type (WT) control mice.  Exocytotic release was induced by the application of a single, biphasic 
electrical stimulus pulse (350µA current, 4ms duration).
8
 Upon analyzing brain slices from 
subjects at ages ranging from 6 to 14 weeks, a dramatic attenuation of DA release was found in 
R6/2 mice compared to WT mice. This attenuation progressively worsened with age, in 
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agreement with diminished locomotor activity.
8
  Experiments in which exogenous DA was 
iontophoretically injected revealed no difference in the extracellular space due to neuronal 
atrophy in R6/2 mice in comparison to WT controls.
39
  Thus, the attenuation in DA release is not 
simply a result of neurotransmitter dilution, but rather that DA neurons in the striatum have a 
diminished capacity for DA release.   
The plots of stimulated release were also modeled using simplex modeling software 
developed by Prof. Paul Garris (Illinois State University, Normal, IL). Values of Vmax, the 
maximum rate of uptake by the DA transporter, were extracted from these modeled curves.  
Importantly, Vmax was unchanged between genotype and age group, indicating that uptake was 
not impaired in R6/2 mice.  Moreover, the uptake inhibition constants (Ki) for COC and METH, 
which indicate how strongly the drugs bind to the DA transporter protein molecules, did not 
significantly differ between R6/2 and WT control mice.  Collectively, these results suggest that 
impairments in DA release, rather than uptake, are responsible for locomotor abnormalities 
observed in R6/2 mice, either in the presence or absence of psycho-stimulants.
8
 Similar FSCV 
experiments have revealed that DA release is also attenuated in R6/1 HD model mice.
40
 These 
findings are consistent with those found in R6/2 mice in that DA release attenuation progressed 
with age and the onset of the overt phenotype.  Interestingly, DA uptake, again measured as 
Vmax, was impaired in R6/1 HD model mice.  Although the specific mechanisms underlying this 
impairment are not clear, the ages of the mice may also play a role, given that R6/1 mice develop 
significant deficits in rotorod performance at 13 to 20 weeks of age, while R6/2 mice become 







3.1.6 Regional differences in DA release attenuation in R6/2 Mice  
Previous work in our group has determined sub-second alterations in dopaminergic 
neurotransmission in R6/2 HD model mice utilizing fast-scan cyclic voltammetry (FSCV). FSCV 
at the surface of carbon-fiber microelectrodes offers high spatial and temporal resolution, which 
facilitates the investigation of electroactive biomolecules, such as neurotransmitters, at 
physiologically relevant timescales.
43,44
 In previous work, it was established that electrically 
evoked DA release is severely attenuated in the dorsolateral striatum of brain slices taken from 
R6/2 mice.
8,39,45
 Here, we have determined stimulated dopamine release is altered in the 
subdivisions of the striatum, including the dorsal lateral (DL), dorsal medial (DM), ventral lateral 
(VL), and ventral medial (VM) regions. 
While there exists no clear neurophysiological differences in these regions, studies have 
identified the role of each region in controlling behavior.
46
 Furthermore, as mentioned in Chapter 
1 of this document, there exists an input gradient throughout the striatum. This gradient is 
established by two unique dopaminergic inputs to the striatum from the mesolimbic pathway, 
that  project from the ventral tegmental area via A10 neurons, and nigrostriatal pathway, which 
projects from the substantia nigra pars compacta via A9 neurons.
47
 The A9 neurons project to the 
dorsal striatum from the VTA and the A10 neurons project to the ventral striatum from 
substantia nigra pars compacta.
48
 Differing functionalities have resulted from this gradient. 
Motor function and execution are associated with the dorsal striatum.
48–51
 The ventral striatum is 
associated with appetitive motivation and reinforcement learning.
48,52–54
 In healthy humans and 
rats, there exists an intrinsic dorsal to ventral gradient for stimulated dopamine release.
48
 
Previous studies have shown DA dysregulation in HD model mice.
8,39,45,55,56
 To date, differences 
in striatal regional release and their implications in the mechanism of HD pathogenesis have yet 
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to be addressed. Here, we have uncovered statistically significant regional differences in DA 
release, in addition to investigating alterations in dopamine transporter (DAT) function and DA 
release in response to stress from a high pulse stimulation train using FSCV. 
The primary mode of dopamine clearance from the synaptic cleft is reuptake by 
dopamine transporter channel proteins back into the neuron.
57
 These integral proteins control the 
time by which DA may reside in the synaptic cleft and mediate DA diffusion.
58
 Modeling of 
FSCV traces taken from HD and WT mice have been used to deduce the DAT reuptake rate is 
unaltered in HD mice. Furthermore, the uptake inhibition constants were unchanged between 
experimental groups for cocaine and methamphetamine binding, which suggests that drugs bind 
to the dopamine transporter proteins at normal rates.
8
 Unlike the modeled data, our 
autoradiography results indicate that HD plays an important role in affecting the DAT population 




The purpose of this work was to determine if DA dysregulation is regionally dependent 
within the striatum. Here, three important facets of HD pathogenesis are explored in R6/2 model 
mice. First, we investigated the effect of R6/2 mouse age on dopaminergic neuronal release in all 
four quadrants of the striatum. This was done using FSCV in R6/2 and wild type (WT) mice at 7-
9, 10-12, and 12-14 weeks of age with the goal of determining if the extent of overt motor 
phenotypic symptoms corresponds to further alterations of the dopaminergic system, according 
to region in the striatum. Statistically significant regional release differences were seen. Second, 
the effect of stimulation frequency during high pulse stimulations on regional release was 
analyzed. This was done to determine if dopamine reserve pool release was altered by the HD 
phenotype, again according to location in the striatum. It was found that under intense 
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stimulation, there is a difference in DA release in the dorsal striatum, but not in the ventral 
striatum. Third, autoradiograpy of the dopamine transporter was conducted to investigate the 
findings of others from computational modeling studies that the rate of dopamine uptake is 
unaltered by HD according to age and striatal region. Our results indicate generalized DAT 
depletions by genotype. 
 
3.2 Experimental Procedures 
 
3.2.1 Animals  
All experiments were carried out in accordance with the National Institutes of Health 
Guide for the Care and Use of Laboratory Animals. All procedures were approved by the 
University of Kansas Institutional Animal Care and Use Committee.  Male R6/2 [B6CBA-
Tg(HDexon1)62Gpb] and WT mice (Jackson Laboratories; Bar Harbor, ME, USA) were housed 
5 per cage in the University of Kansas Animal Care Unit.  Food and water was available ad 
libitum. Mice were maintained on a 12 hour light/dark cycle with lights on at 6:00 AM and lights 
out at 6:00 PM.  A temperature of 70 ± 2 °C and humidity level of 50 ± 20% was maintained.    
 
3.2.2 Electrode fabrication 
Carbon-fiber cylindrical microelectrodes were fabricated as previously described.
61,62
  
Briefly, 7µm carbon-fiber purchased from Goodfellow Cambridge Ltd. (Huntingdon, England) 
was loaded into glass capillaries (4in, 1.2mm OD; A-M Systems, Inc. Carlsborg, WA, USA) and 
pulled using a heated coil puller (Narishige International USA, East Meadow, NY, USA). 
Carbon-fiber tips were then cut with a scalpel 25 µm from the end of the glass seal. Electrodes 
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were then sealed by dipping into a well-mixed epoxy mixture of  0.24g EPI-CURE 3234 Curing 
Agent (lot FCXC4114/0886GG) and 2.00g EPON Resin 815C (lot HADN0003/1307GG). 
Excess resin was removed by dipping several times in toluene and electrodes were then baked 
for 1 hour at 100°C. The electrodes were back-filled with 0.5 M potassium acetate in order to 
establish an electrical connection between the carbon-fiber and the inserted silver wire.  
 
3.2.3 Brain slices  
Brain slices were harvested as previously described.
56
  In summary, rats were deeply 
anesthetized by isoflurane inhalation and decapitated. The brain was then immediately removed 
and placed into ice-cold artificial cerebral spinal fluid (aCSF). The aCSF solution contained the 
following concentrations: 2.5 mM KCl, 126 mM NaCl, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.4 
mM CaCl2, 1.2 mM MgCl2, 20 mM HEPES, 11 mM D-glucose. The pH was adjusted to 7.4 with 
NaOH. To ensure the tissue received ample oxygen, the aCSF was continuously bubbled with 
95% O2/5% CO2 throughout the experiment. After chilling for one minute, the cerebellum was 
removed and the brain was bisected longitudinally using a sterile razor blade. The sample was 
then stored at -80°C and saved for HPLC analysis. The other hemisphere of the brain was then 
glued to a plate against a cube of agar for support. Several 300µm coronal brain slices were then 
obtained using a vibratome (Leica Microsystems, Bannockburn, IL, USA). In a typical recording 
session, a single striatal brain slice was transferred to a perfusion chamber where oxygenated 
aCSF, maintained at 34ºC using a thermostatted perfusion chamber and in-line heater, flowed 





3.2.4 Electrochemical measurements using FSCV 
Procedures for measuring DA release and uptake with background-subtracted FSCV have 
been described in detail previously.
55, 56,64,65
 Briefly, a pre-calibrated cylinder carbon-fiber 
microelectrode was inserted 100µm into the brain slice using micromanipulators and a 
stereoscope. The electrode was positioned between two biphasic stimulating electrodes (A-M 
Systems Inc, Carlsborg, WA, USA) in the striatum. For DA detection, a triangular waveform 
starting at -0.4V, scanning up to 1.0V, and back to -0.4V, was applied to the carbon-fiber 
microelectrode at a scan rate of 300V/s and an update rate of 10 Hz. Dopamine release was 
evoked both by applying a single, biphasic pulse (350 µA, 4 ms total duration) and by applying 
120 pulse stimulations. For the 120-pulse stimulations, DA release was measured using 
stimulation frequencies of 20, 30, 40,50, and 60 Hz at each of the four quadrants of the striatum 
(DL, DM, VM, and VL). At each location, DA release was measured starting with the lowest 
stimulation frequency to the highest. The peak current after stimulation was used for all release 
measurements and there was a 5 minute recovery period between each measurement. The current 
measured from DA oxidation was plotted versus potential and the successive voltammograms 
were plotted versus time. 
 
3.2.5 Autoradiography of Dopamine Transporter  
Regional densities of DAT were determined by [
3
H]WIN 35,428 autoradiography 
according to a modification of the methods of Coulter et al.
66
  Briefly, brains were collected, 
frozen in isopentane, and stored at -70º C until sectioning.  Coronal sections (20 µm) were cut on 
a cryostat.  Duplicate sections were incubated with 4 nM [
3
H]WIN 35,428 (Perkin-Elmer, SA = 
84 Ci/mmol) in buffer (50 mM NaHPO4, 50 mM NaCl, pH 7.4) for one hour on ice.  Non-
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specific binding was defined in the presence of 50 µM cocaine.  After incubation, slides were 
dipped in ice-cold buffer, washed for two consecutive two minute periods in ice-cold buffer, 
dipped in ice-cold deionized water, and dried.  Radiolabeled sections were then opposed to 
3
H-
Hyperfilm (Amersham, Arlington Heights, IL) with [
3
H]methylmethacrylate autoradiography 
standards for 19 days. 
 3
H-Hyperfilm was developed according to the manufacturer’s 
instructions.  Brain sections were then stained with cresyl violet. Autoradiographic images were 
digitized and quantified using ImageJ.  A Rodbard plot was used to describe the relationship 
between optical density and radioactivity.  Measurements represent average pixel optical density 
by volume analysis.  Brain regions were identified according to the atlas of Paxinos and 
Watson.
67
  The caudate nucleus was divided into quadrants and sampled bilaterally at five levels. 
Values were averaged to yield a binding density for each animal.    Data are reported as specific 
binding (fmol/mg tissue equivalent) and analyzed for effect of treatment and quadrant by two-
way ANOVA (SigmaPlot 12.5). 
 
3.2.5 Statistics  
Statistical analyses were conducted using GraphPad Prism software (GraphPad Software 
Inc., San Diego, CA, USA).  For statistical analyses, n = the number of rats.  Data are given as 
mean ± SEM. 
 
3.3 Results and Discussion  
 
It has been previously been shown that single pulse electrically evoked DA release is 
severely attenuated in the striatum of R6/2 transgenic mice.
8,39
 The electrochemical 
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measurements performed in these studies were taken from the dorsolateral caudate. 
Experimenters have chosen to take measurements in this brain region as it is known to be 
exclusively innervated from the nigrostriatal pathway
8,68
 which is known to degenerate in HD.
69–
72
 The vast majority of FSCV research performed has been done on the dorsolateral caudate, but 
little has been done to determine if DA release is affected in other striatal regions. Regional 
differences in DA release in the striatum may account for or provide insight into how HD 
progresses. Here, we have quantified electrically evoked DA release with FSCV in the four 
quadrants of R6/2 HD model mice and their WT counterparts to probe for possible regional 






3.3.1 Striatal Dopamine Release  
 
Figure 1. Dopamine release comparison of a wild-type control (A) and an R6/2 mouse (B). 
Representative color plots and stimulated DA release plots, sampled along the horizontal dashed 
lines on the color plots, are shown.  Cyclic voltammograms, sampled along the vertical dashed 
lines on the color plots, are shown directly above the stimulated release plots to confirm the 




Electrically-evoked DA release was measured by FSCV in the dorsolateral dorsal lateral 
(DL), dorsal medial (DM), ventral medial (VM), and ventral lateral (VL) quadrants of the 
striatum in coronal brain slices. Four measurements were taken in each quadrant and averaged to 
account for possible heterogeneity between single measurements. Representative raw data for a 
12 week-old R6/2 and WT mouse can be seen in Fig. 1. The cyclic voltammograms in Fig. 1 
confirm that DA is the analyte being measured. The color plots show a series of unfolded and 
stacked CVs with a color-coded current response. The representative current responses taken 
from the DL striatum in Figure 1B suggest, as expected, that DA release is attenuated in R6/2 
mice.  
It was further determined that single-pulse electrically-evoked DA release is attenuated in 
all quadrants of the striatum when compared to WT controls: 18% of WT averaged across all 
brain regions [DA]max (Fig. 2; two-way ANOVA , p < 0.01, n = 5). Our initial studies suggested 
that DA release attenuation was more severe in the dorsal striatum. To gain further insight as to 
how regional differences in stimulated DA release progresses over time, measurements were 





Figure 2. Comparative DA release concentrations by striatal region for R6/2 and WT mice. (A) 
Image of coronal brain slice containing the striatum. The four quadrants sampled from within the 
striatum are outlined. (B) [DA]max for R6/2 mice in comparison to WT controls shown per region 




3.3.2 Regional differences in dopamine release attenuation  
The progression of DA release attenuation by region can be seen in Fig. 3. At 7-9 weeks 
of age, there was no significant regional differences in electrically stimulated DA release for 
both R6/2 and WT mice (Fig. 3A; separate one-way ANOVA for R6/2 and WT; R6/2 p > 0.05, n 
= 6; WT p > 0.05, n = 5). At 10-11 weeks, there is a significant regional difference in stimulated 
DA release for R6/2 mice (Fig. 3B; one-way ANOVA, p < 0.05, n = 6). There was no significant 
regional difference in release for WT mice (Fig. 3B; one-way ANOVA, p > 0.05, n = 6) at this 
age group. At 12-14 weeks of age, which is the age at which the HD phenotype is most severe, 
stimulated DA release in the dorsal striatum is 42%  percent of release in the ventral striatum 
(Fig. 3C; one-way ANOVA, p < 0.005, n = 5). There was no significant regional difference in 
stimulated DA release for WT mice for this age group (Fig. 3C; one-way ANOVA, p > 0.05, n = 
5). There is therefore a gradient in the attenuation of DA release caused by the HD mutation in 
R6/2 transgenic mice.  Thus, changes in DA release are not a consequence of regional alterations 






Figure 3. Comparative DA release by region in R/62 and WT mice. A) Normalized [DA]max by 
striatal region for 7-9 week-old R6/2 and WT mice (two-way ANOVA, p > 0.05, n = 5 WT and n 
= 6 R6/2). B) Normalized [DA]max by striatal region for 10-11 week-old R6/2 and WT mice 
(two-way ANOVA, p < 0.05, n = 6). C) Normalized [DA]max by striatal region for 12-14 week-
old R6/2 and WT mice (two-way ANOVA, p < 0.001, n = 5).  
   
  
3.3.3 Regional differences in DA release with 120 stimulus pulses  
According to the generalized three-pool model of vesicular neurotransmitter storage 
within a neuron, there are three distinct neurotransmitter pools. These include the readily 
releasable, recycling, and reserve pools.
73–75
 The readily releasable pool contains 1-2 % of stored 
vesicles and undergoes release upon mild stimulation. The recycling pool accounts for 5-20 % of 
vesicles and replenishes the readily releasable pool after its depletion.
76–78
 The reserve pool 
contains the majority of stored vesicles (80-90%) and is mobilized under prolonged neuronal 
stimulation. Electrical stimulation in conjunction with FSCV has been previously used to obtain 
information regarding vesicular storage in R6/2 mice.
8,39,55
 Specifically, it has previously been 
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shown there is a significant difference in DA release at high stimulation frequencies (50 and 
60Hz) in the dorsolateral striatum when applying 120 stimulation pulse trains.
55
 This multiple 
stimulation pulse study, along with a separate pharmacological manipulation, lead to the 
conclusion that proper reserve pool DA storage is negatively impacted by HD in the dorsal 
lateral striatum.  
  To further elucidate the impact of HD on regional DA release in the striatum, we chose 
to measure DA release under prolonged electrical stimulation, which can lead to reserve pool 
mobilization.
45,55,78–80
 To accomplish this, 120 stimulation pulses were separately applied to the 
DL, DM, VM, and VL striatum of brain slices harvested from 12 week-old R6/2 and WT mice. 
The stimulated DA release was measured via FSCV at carbon-fiber microelectrodes. One 
measurement was taken at each frequency in each of the four quadrants of the striatum and DA 
release was measured as the highest point of stimulated release [DA]stim. These measurements 
were all taken in order from lowest to highest stimulation frequency. Representative raw data for 
a 12 week-old R6/2 and WT brain slice subjected to 120 stimulation pulses at 60Hz can be seen 





Figure 4. Representative raw data for a 12 week-old R6/2 and WT brain slice subjected to 120 
stimulation pulses at 60Hz from the dorsolateral caudate. Representative concentration response 
to electrical stimulus are shown along with their cyclic voltammograms, confirming the presence 




As is expected, stimulated release response (current vs time) appears to be diminished in 
the DL striatum of the R6/2 mouse in comparison to the WT trace. All values of [DA]stim for 
brain slices subjected to 120 stimulation pulses at varying frequencies for each quadrant of the 
striatum can be seen in Fig. 5. Similar to the results found by Ortiz et al., there appears to be a 
frequency dependent increase in [DA]stim for WT mice in the DL striatum, however, this is not 
supported statistically (Fig 5a, one-way ANOVA, p > 0.05, n = 5). This is also true for 
measurements taken from WT slices for all other regions of the striatum (Fig 5B-D, one-way 
ANOVA, p > 0.05 n = 5). There was no frequency dependent change in [DA]stim in any region of 
slices obtained from R6/2 brain slices (Fig 5A-D, one-way ANOVA, p > 0.05, n = 4). Out of the 
four regions sampled, [DA]stim is only significantly attenuated in the dorsal striatum (DL Fig. 5A, 





Figure 5. 120 pulse stimulation with altering frequency per region. A) [DA]stim in the dorsal 
lateral striatum. B) [DA]stim in the dorsal medial striatum. C) [DA]stim in the ventral medial 
striatum D) [DA]stim in the ventral lateral striatum. There was no significant difference in 
frequency dependent release in WT or R6/2 mice in any striatum region (Fig 5A-D, one-way 
ANOVA, p > 0.05 n = 5). Out of the four regions sampled from, [DA]stim is only significantly 
attenuated in the dorsal striatum (DL Fig. 5A, two-way ANOVA, p < 0.005; DM Fig. 5B, two-




3.3.4 Regional distribution of the dopamine transporter  
It is clear that that there is a dorsal-to-ventral gradient of attenuation in electrically 
evoked dopamine release that is caused by the HD mutation in R6/2 mice. These data suggest 
that the dorsal striatum is more vulnerable to neurological malfunction in HD. These data are 
consistent with the clinically-determined dorsal-to-ventral gradient of neurodegeneration in 
humans. This gradient may therefore be at least partially responsible for the observed gradient of 
impaired DA release. To further investigate the cause of this release gradient, we chose to 
investigate how the dopamine transporter (DAT) distribution may be affected in the R6/2 
striatum. DAT function is the primary route by which DA released into the synaptic cleft may be 
cleared. These integral protein channels also mediate DA diffusion in the synaptic cleft.
58
 The 
ability of the transporter to efficiently clear DA is critical for ceasing postsynaptic signaling. 





 Given that overt phenotype of HD includes chorea in 
90% of patients,
7
 we hypothesized dysfunctions in cellular signaling caused by attenuated 
clearance of DA may contribute to the onset of these symptoms.  
 The density of DAT was found through autoradiography of the transporter using 
[
3
H]WIN 35,428. Representative striatal slices after [
3
H]WIN 35,428 binding are shown in 
Figure 6 alongside cresyl violet only staining. [
3
H]WIN 35,428 staining proportional to DAT 
levels is markedly decreased in HD R6/2 mice. The bilateral distribution of DAT in the striatum 
was 43.9% in HD mice at 12 weeks age in comparison to WT controls (two-way ANOVA, 
p<0.0001). Consistent with these results are DAT levels in the nucleus accumbens, which for HD 
mice had DAT levels that were 43.1% of WT controls. Although there is a significant difference 
in the amount of DAT present in the striatum of R6/2 mice in comparison to their WT controls, 
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there was no regional difference in DAT distribution in R6/2 mice (one-way ANOVA p > 0.05) 
(Fig. 6B). This lack of differential distribution of DAT suggests that the regional difference in 
stimulated DA release is not attributed solely to a simple dorsal-to-ventral gradient of 
neurodegeneration.    
 
 
Figure 6.  Autoradiographic localization of [
3
H]WIN 35,428-labeled sites in control and 
Huntington’s mice.  Data shown represent total binding.  Autoradiograms shown are 







Others have reported through modeling of FSCV traces that the uptake is unchanged by 
the HD phenotype in R6/2 mice.
8
 The maximum rate of DA uptake (Vmax) is proportional to the 
number of active DAT channel protein molecules. However, these findings strongly suggest that 
DA clearance from the synaptic cleft should be impaired since more than half of the channels are 
not present in R6/2 mice. The motor dysfunctions seen in R6/2 mice and HD patients may well 
be contributed to by the inability of DAT channels to effectively clear DA from the synapse.  
Studies in DAT knockout mice have also shown that DA synthesis rates are doubled concurrent 
with a 90% decrease in tyrosine hydroxylase concentration and enhanced neuronal 
degeneration.
83
 Given that DAT also plays a key role in modulating presynaptic dopamine 
homeostasis,
83
 suppression of the number of DAT channels may culminate in enhanced DA 
synthesis and elevated degeneration in HD mice, as was seen in genetically engineered DAT-KO 
mice. Elevated DA levels have been shown to cause the degeneration of neurons when DA is 




 Given extracellular DA release 
was sharply attenuated by genotype, it is possible that the loss of DAT channels induced elevated 
intracellular DA synthesis. This alteration may lead to the degeneration and changes in the 
dopaminergic system that are seen here in R6/2 mice. Total DA content in the striatal neuron cell 
bodies would need to be assayed to test this hypothesis. 
 
 
3.4 Conclusion  
 
In conclusion, it was determined that electrically-evoked DA release is progressively 
attenuated in the striatum of R6/2 mice and that this attenuation is more severe in the dorsal 
striatum. Moreover, when applying a 120 stimulation pulse-train, it was found that DA release 
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was only significantly attenuated in the dorsal striatum, suggesting that the ventral striatum is 
less vulnerable to the mechanism of impairment caused by the HD mutation. In order to see if 
regional differences involved the density distribution of the dopamine transporter (DAT), 
autoradiography using [
3
H]WIN 35,428 was performed. It was found that the density distribution 
of DAT is significantly less in R6/2 mice in comparison to their WT controls; however, there 
were no significant regional differences, suggesting that the regional differences found in DA 
release attenuation is not simply a result of differential neurodegeneration. These data 
collectively suggest that the genetic mutation involved in HD leads to the increased vulnerability 







(1) Martin, J. B., and Gusella, J. F. (1986) Huntington’s disease. N Engl J Med 315, 1267–1276. 
(2) Snell, R. G., MacMillan, J. C., Cheadle, J. P., Fenton, I., Lazarou, L. P., Davies, P., 
MacDonald, M. E., Gusella, J. F., Harper, P. S., and Shaw, D. J. (1993) Relationship between 
trinucleotide repeat expansion and phenotypic variation in Huntington’s disease. Nat. Genet. 4, 
393–397. 
(3) The Huntington’s Disease Collaborative Research Group, MacDonald, M. E., Ambrose, C. 
M., Duyao, M. P., Myers, R. H., Lin, C., Srinidhi, L., Barnes, G., Taylor, S. A., James, M., and 
Groot, N. (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on 
Huntington’s disease chromosomes. Cell 72, 971–983. 
(4) Pringsheim, T., Wiltshire, K., Day, L., Dykeman, J., Steeves, T., and Jette, N. (2012) The 
incidence and prevalence of Huntington’s disease: A systematic review and meta-analysis. Mov. 
Disord. 27, 1083–1091. 
(5) Andrew, S. E., Goldberg, Y. P., Kremer, B., Telenius, H., Theilmann, J., Adam, S., Starr, E., 
Squitieri, F., Lin, B., and Kalchman, M. A. (1993) The relationship between trinucleotide (CAG) 
repeat length and clinical features of Huntington’s disease. Nat. Genet. 4, 398–403. 
(6) Duyao, M., Ambrose, C., Myers, R., Novelletto, A., Persichetti, F., Frontali, M., Folstein, S., 
Ross, C., Franz, M., and Abbott, M. (1993) Trinucleotide repeat length instability and age of 
onset in Huntington’s disease. Nat. Genet. 4, 387–392. 
(7) MacMillan, J. C., Snell, R. G., Tyler, A., Houlihan, G. D., Fenton, I., Cheadle, J. P., Lazarou, 
L. P., Shaw, J. D., and Harper, P. S. (1993) Molecular analysis and clinical correlations of the 
Huntington’s disease mutation. The Lancet 342, 954–958. 
111 
 
(8) Johnson, M. A., Rajan, V., Miller, C. E., and Wightman, R. M. (2006) Dopamine release is 
severely compromised in the R6/2 mouse model of Huntington’s disease. J. Neurochem. 97, 
737–746. 
(9) Zuccato, C., Valenza, M., and Cattaneo, E. (2010) Molecular Mechanisms and Potential 
Therapeutical Targets in Huntington’s Disease. Physiol. Rev. 90, 905–981. 
(10) Huntington, G. (2004) On chorea. Landmarks Med. Genet. Class. Pap. Comment. 51, 4. 
(11) Kremer, B. (2002), in Huntington’s disease 3rd ed., pp 28–61. Oxford University Press, 
Oxford ; New York. 
(12) Politis, M., Pavese, N., Tai, Y. F., Tabrizi, S. J., Barker, R. A., and Piccini, P. (2008) 
Hypothalamic involvement in Huntington’s disease: an in vivo PET study. Brain 131, 2860–
2869. 
(13) Penney, J. B., Young, A. B., Shoulson, I., Starosta-Rubenstein, S., Snodgrass, S. R., 
Sanchez-Ramos, J., Ramos-Arroyo, M., Gomez, F., Penchaszadeh, G., and Alvir, J. (1990) 
Huntington’s disease in venezuela: 7 years of follow-up on symptomatic and asymptomatic 
individuals. Mov. Disord. 5, 93–99. 
(14) Barbeau, A., Duvoisin, R. C., Gerstenbrand, F., Lakke, J. P., Marsden, C. D., and Stern, G. 
(1981) Classification of extrapyramidal disorders. Proposal for an international classification and 
glossary of terms. J. Neurol. Sci. 51, 311. 
(15) Hayden, M. R. (1981) Huntington’s chorea. Springer-Verlag Berlin. 
(16) Lanska, D. J., Lanska, M. J., Lavine, L., and Schoenberg, B. S. (1988) Conditions 
associated with Huntington’s disease at death: a case-control study. Arch. Neurol. 45, 878. 
(17) Lanska, D. J., Lavine, L., Lanska, M. J., and Schoenberg, B. S. (1988) Huntington’s disease 
mortality in the United States. Neurology 38, 769–769. 
112 
 
(18) Kandel, E. R., Schwartz, J. H., and Jessell, T. M. (2000) Principles of neural science. 
McGraw-Hill New York. 
(19) DiFiglia, M., Sapp, E., Chase, K., Schwarz, C., Meloni, A., Young, C., Martin, E., 
Vonsattel, J.-P., Carraway, R., and Reeves, S. A. (1995) Huntingtin is a cytoplasmic protein 
associated with vesicles in human and rat brain neurons. Neuron 14, 1075–1081. 
(20) Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., 
Scherzinger, E., Wanker, E. E., Mangiarini, L., and Bates, G. P. (1997) Formation of neuronal 
intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD 
mutation. Cell 90, 537–548. 
(21) Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., 
Bates, G. P., Davies, S. W., Lehrach, H., and Wanker, E. E. (1997) Huntingtin-encoded 
polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell 90, 
549–558. 
(22) Cattaneo, E., Zuccato, C., and Tartari, M. (2005) Normal huntingtin function: an alternative 
approach to Huntington’s disease. Nat. Rev. Neurosci. 6, 919–930. 
(23) Ikeda, H., Yamaguchi, M., Sugai, S., Aze, Y., Narumiya, S., and Kakizuka, A. (1996) 
Expanded polyglutamine in the Machado–Joseph disease protein induces cell death in vitro and 
in vivo. Nat. Genet. 13, 196–202. 
(24) Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., 
Lawton, M., Trottier, Y., Lehrach, H., and Davies, S. W. (1996) Exon 1 of the< i> HD</i> Gene 
with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in 
Transgenic Mice. Cell 87, 493–506. 
113 
 
(25) Charvin, D., Vanhoutte, P., Pagès, C., Borelli, E., and Caboche, J. (2005) Unraveling a role 
for dopamine in Huntington’s disease: the dual role of reactive oxygen species and D2 receptor 
stimulation. Proc. Natl. Acad. Sci. U. S. A. 102, 12218–12223. 
(26) Li, J. Y., Popovic, N., and Brundin, P. (2005) The use of the R6 transgenic mouse models of 
Huntington’s disease in attempts to develop novel therapeutic strategies. NeuroRx 2, 447–464. 
(27) Hodgson, J. G., Agopyan, N., Gutekunst, C.-A., Leavitt, B. R., LePiane, F., Singaraja, R., 
Smith, D. J., Bissada, N., McCutcheon, K., and Nasir, J. (1999) A YAC mouse model for 
Huntington’s disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective 
striatal neurodegeneration. Neuron 23, 181–192. 
(28) Van Raamsdonk, J. M. (2005) Selective degeneration and nuclear localization of mutant 
huntingtin in the YAC128 mouse model of Huntington disease. Hum. Mol. Genet. 14, 3823–
3835. 
(29) Van Raamsdonk, J. M. (2005) Cognitive Dysfunction Precedes Neuropathology and Motor 
Abnormalities in the YAC128 Mouse Model of Huntington’s Disease. J. Neurosci. 25, 4169–
4180. 
(30) Levine, M. S., Cepeda, C., Hickey, M. A., Fleming, S. M., and Chesselet, M.-F. (2004) 
Genetic mouse models of Huntington’s and Parkinson’s diseases: illuminating but imperfect. 
Trends Neurosci. 27, 691–697. 
(31) Khan, A. S., and Michael, A. C. (2003) Invasive consequences of using micro-electrodes 
and microdialysis probes in the brain. TrAC Trends Anal. Chem. 22, 503–508. 
(32) Borland, L. M., Shi, G., Yang, H., and Michael, A. C. (2005) Voltammetric study of 
extracellular dopamine near microdialysis probes acutely implanted in the striatum of the 
anesthetized rat. J. Neurosci. Methods 146, 149–158. 
114 
 
(33) Westerink, B. H. (1995) Brain microdialysis and its application for the study of animal 
behaviour. Behav. Brain Res. 70, 103–124. 
(34) Nandi, P., and Lunte, S. M. (2009) Recent trends in microdialysis sampling integrated with 
conventional and microanalytical systems for monitoring biological events: A review. Anal. 
Chim. Acta 651, 1–14. 
(35) Petersén,  å., Puschban, Z., Lotharius, J., NicNiocaill, B., Wiekop, P., O’Connor, W. T., and 
Brundin, P. (2002) Evidence for Dysfunction of the Nigrostriatal Pathway in the R6/1 Line of 
Transgenic Huntington’s Disease Mice. Neurobiol. Dis. 11, 134–146. 
(36) Fernandez-Gomez, F. J., Galindo, M. F., Gómez-Lázaro, M., Yuste, V. J., Comella, J. X., 
Aguirre, N., and Jordán, J. (2005) Malonate induces cell death via mitochondrial potential 
collapse and delayed swelling through an ROS-dependent pathway. Br. J. Pharmacol. 144, 528–
537. 
(37) Callahan, J. W., and Abercrombie, E. D. (2011) In vivo Dopamine Efflux is Decreased in 
Striatum of both Fragment (R6/2) and Full-Length (YAC128) Transgenic Mouse Models of 
Huntington’s Disease. Front. Syst. Neurosci. 5. 
(38) Hickey, M. A., Reynolds, G. P., and Morton, A. J. (2002) The role of dopamine in motor 
symptoms in the R6/2 transgenic mouse model of Huntington’s disease. J. Neurochem. 81, 46–
59. 
(39) Johnson, M. A., Villanueva, M., Haynes, C. L., Seipel, A. T., Buhler, L. A., and Wightman, 
R. M. (2007) Catecholamine exocytosis is diminished in R6/2 Huntington’s disease model mice. 
J. Neurochem. 103, 2102–2110. 
(40) Ortiz, A. N., Kurth, B. J., Osterhaus, G. L., and Johnson, M. A. (2011) Impaired dopamine 
release and uptake in R6/1 Huntington’s disease model mice. Neurosci. Lett. 492, 11–14. 
115 
 
(41) Carter, R. J., Lione, L. A., Humby, T., Mangiarini, L., Mahal, A., Bates, G. P., Dunnett, S. 
B., and Morton, A. J. (1999) Characterization of progressive motor deficits in mice transgenic 
for the human Huntington’s disease mutation. J. Neurosci. 19, 3248–3257. 
(42) Lüesse, H.-G., Schiefer, J., Spruenken, A., Puls, C., Block, F., and Kosinski, C. M. (2001) 
Evaluation of R6/2 HD transgenic mice for therapeutic studies in Huntington’s disease: 
behavioral testing and impact of diabetes mellitus. Behav. Brain Res. 126, 185–195. 
(43) Baur, J. E., Kristensen, E. W., May, L. J., Wiedemann, D. J., and Wightman, R. M. (1988) 
Fast-scan voltammetry of biogenic amines. Anal. Chem. 60, 1268–1272. 
(44) Robinson, D. L., Venton, B. J., Heien, M. L., and Wightman, R. M. (2003) Detecting 
subsecond dopamine release with fast-scan cyclic voltammetry in vivo. Clin. Chem. 49, 1763–
1773. 
(45) Ortiz, A. N., Oien, D. B., Moskovitz, J., and Johnson, M. A. (2011) Quantification of 
reserve pool dopamine in methionine sulfoxide reductase A null mice. Neuroscience 177, 223–
229. 
(46) Voorn, P., Vanderschuren, L. J. M. ., Groenewegen, H. J., Robbins, T. W., and Pennartz, C. 
M. . (2004) Putting a spin on the dorsal–ventral divide of the striatum. Trends Neurosci. 27, 468–
474. 
(47) Zahm, D. S., Cheng, A. Y., Lee, T. J., Ghobadi, C. W., Schwartz, Z. M., Geisler, S., Parsely, 
K. P., Gruber, C., and Veh, R. W. (2011) Inputs to the midbrain dopaminergic complex in the 
rat, with emphasis on extended amygdala-recipient sectors. J. Comp. Neurol. 519, 3159–3188. 
(48) Calipari, E. S., Huggins, K. N., Mathews, T. A., and Jones, S. R. (2012) Conserved dorsal–
ventral gradient of dopamine release and uptake rate in mice, rats and rhesus macaques. 
Neurochem. Int. 61, 986–991. 
116 
 
(49) Volkow, N. D., Wang, G.-J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y.-S., Hitzemann, 
R., and Pappas, N. (1998) Dopamine transporter occupancies in the human brain induced by 
therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155, 1325–1331. 
(50) Palmiter, R. D. (2008) Dopamine Signaling in the Dorsal Striatum Is Essential for 
Motivated Behaviors. Ann. N. Y. Acad. Sci. 1129, 35–46. 
(51) Reep, R. L., Cheatwood, J. L., and Corwin, J. V. (2003) The associative striatum: 
Organization of cortical projections to the dorsocentral striatum in rats. J. Comp. Neurol. 467, 
271–292. 
(52) Jocham, G., Klein, T. A., and Ullsperger, M. (2011) Dopamine-Mediated Reinforcement 
Learning Signals in the Striatum and Ventromedial Prefrontal Cortex Underlie Value-Based 
Choices. J. Neurosci. 31, 1606–1613. 
(53) Kelley, A. E. (2004) Ventral striatal control of appetitive motivation: role in ingestive 
behavior and reward-related learning. Neurosci. Biobehav. Rev. 27, 765–776. 
(54) Lynd-Balta, E., and Haber, S. N. (1994) The organization of midbrain projections to the 
ventral striatum in the primate. Neuroscience 59, 609–623. 
(55) Ortiz, A. N., Kurth, B. J., Osterhaus, G. L., and Johnson, M. A. (2010) Dysregulation of 
intracellular dopamine stores revealed in the R6/2 mouse striatum. J. Neurochem. 112, 755–761. 
(56) Ortiz, A. N., Osterhaus, G. L., Lauderdale, K., Mahoney, L., Fowler, S. C., von Hörsten, S., 
Riess, O., and Johnson, M. A. (2012) Motor function and dopamine release measurements in 
transgenic Huntington’s disease model rats. Brain Res. 1450, 148–156. 
(57) Wayment, H. K., Schenk, J. O., and Sorg, B. A. (2001) Characterization of extracellular 
dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine 
oxidase inhibition. J. Neurosci. 21, 35–44. 
117 
 
(58) Sesack, S. R., Hawrylak, V. A., Matus, C., Guido, M. A., and Levey, A. I. (1998) Dopamine 
axon varicosities in the prelimbic division of the rat prefrontal cortex exhibit sparse 
immunoreactivity for the dopamine transporter. J. Neurosci. 18, 2697–2708. 
(59) Moghaddam, B., and Bunney, B. S. (1989) Differential effect of cocaine on extracellular 
dopamine levels in rat medial prefrontal cortex and nucleus accumbens: comparison to 
amphetamine. Synapse 4, 156–161. 
(60) Giros, B., Jaber, M., Jones, S. R., Wightman, R. M., and Caron, M. G. (1996) 
Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine 
transporter. Nature 606–12. 
(61) Kraft, J. C., Osterhaus, G. L., Ortiz, A. N., Garris, P. A., and Johnson, M. A. (2009) In vivo 
dopamine release and uptake impairments in rats treated with 3-nitropropionic acid. 
Neuroscience 161, 940–949. 
(62) Kawagoe, K. T., Jankowski, J. A., and Wightman, R. M. (1991) Etched carbon-fiber 
electrodes as amperometric detectors of catecholamine secretion from isolated biological cells. 
Anal. Chem. 63, 1589–1594. 
(63) Rice, M. E., and Nicholson, C. (1989) Measurement of nanomolar dopamine diffusion using 
low-noise perfluorinated ionomer-coated carbon fiber microelectrodes and high-speed cyclic 
voltammetry. Anal. Chem. 61, 1805–1810. 
(64) Hashemi, P., Danoski, E., Petrovic, J., Keithley, R. B., and Wightman, R. M. (2009) 
Voltammetric Detection of 5-Hydroxytryptamine Release in the Rat Brain. Anal. Chem. 81, 
9462–9471. 
(65) Jackson, B. P., Dietz, S. M., and Wightman, R. M. (1995) Fast-scan cyclic voltammetry of 
5-hydroxytryptamine. Anal. Chem. 67, 1115–1120. 
118 
 
(66) Coulter, C. L., Happe, H. K., Bergman, D. A., and Murrin, L. C. (1995) Localization and 
quantification of the dopamine transporter: comparison of [3 H] WIN 35,428 and [125 I] RTI-55. 
Brain Res. 690, 217–224. 
(67) Paxinos, G., and Watson, C. H. (1986) The rat brain in stereotaxic coordinates 2nd edn. 
Acad. Press N. Y. Rasoolijazi H Joghataie MT Roghani M Nobakht M2007 Benef. Eff. --
Epigallocatechin-3-Gallate Exp. Model Alzheimers Dis. Rat Behav. Anal. Iran Biomed J 11, 
237–243. 
(68) Gerfen, C. R. (1992) The neostriatal mosaic: multiple levels of compartmental organization 
in the basal ganglia. Annu. Rev. Neurosci. 15, 285–320. 
(69) Ferrante, R. J., Kowall, N. W., Beal, M. F., Richardson, E. P., Bird, E. D., and Martin, J. B. 
(1985) Selective sparing of a class of striatal neurons in Huntington’s disease. Science 230, 561–
563. 
(70) Kowall, N. W., Ferrante, R. J., and Martin, J. B. (1987) Patterns of cell loss in Huntington’s 
disease. Trends Neurosci. 10, 24–29. 
(71) Ginovart, N., Lundin, A., Farde, L., Halldin, C., Bäckman, L., Swahn, C.-G., Pauli, S., and 
Sedvall, G. (1997) PET study of the pre-and post-synaptic dopaminergic markers for the 
neurodegenerative process in Huntington’s disease. Brain 120, 503–514. 
(72) Suzuki, M., Desmond, T. J., Albin, R. L., and Frey, K. A. (2001) Vesicular neurotransmitter 
transporters in Huntington’s disease: initial observations and comparison with traditional 
synaptic markers. Synapse 41, 329–336. 
(73) Neves, G., and Lagnado, L. (1999) The kinetics of exocytosis and endocytosis in the 
synaptic terminal of goldfish retinal bipolar cells. J. Physiol. 515, 181–202. 
119 
 
(74) Zucker, R. S., and Regehr, W. G. (2002) Short Term Synaptic Plasticity. Annu. Rev. 
Physiol. 64, 355–405. 
(75) Rizzoli, S. O., and Betz, W. J. (2005) Synaptic vesicle pools. Nat. Rev. Neurosci. 6, 57–69. 
(76) Harata, N., Ryan, T. A., Smith, S. J., Buchanan, J., and Tsien, R. W. (2001) Visualizing 
recycling synaptic vesicles in hippocampal neurons by FM 1-43 photoconversion. Proc. Natl. 
Acad. Sci. 98, 12748–12753. 
(77) Kuromi, H., and Kidokoro, Y. (2003) Two synaptic vesicle pools, vesicle recruitment and 
replenishment of pools at the Drosophila neuromuscular junction. J. Neurocytol. 32, 551–565. 
(78) Richards, D. A., Guatimosim, C., Rizzoli, S. O., and Betz, W. J. (2003) Synaptic vesicle 
pools at the frog neuromuscular junction. Neuron 39, 529–541. 
(79) Heien, M., and Wightman, R. M. (2006) Phasic dopamine signaling during behavior, 
reward, and disease states. Curr. Drug Targets-CNS Neurol. Disord. 5, 99–108. 
(80) Venton, B. J. (2006) Cocaine Increases Dopamine Release by Mobilization of a Synapsin-
Dependent Reserve Pool. J. Neurosci. 26, 3206–3209. 
(81) Cyr, M., Beaulieu, J.-M., Laakso, A., Sotnikova, T. D., Yao, W.-D., Bohn, L. M., 
Gainetdinov, R. R., and Caron, M. G. (2003) Sustained elevation of extracellular dopamine 
causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc. Natl. 
Acad. Sci. 100, 11035–11040. 
(82) Nuber, S., Petrasch-Parwez, E., Winner, B., Winkler, J., von Horsten, S., Schmidt, T., Boy, 
J., Kuhn, M., Nguyen, H. P., Teismann, P., Schulz, J. B., Neumann, M., Pichler, B. J., Reischl, 
G., Holzmann, C., Schmitt, I., Bornemann, A., Kuhn, W., Zimmermann, F., Servadio, A., and 
Riess, O. (2008) Neurodegeneration and Motor Dysfunction in a Conditional Model of 
Parkinson’s Disease. J. Neurosci. 28, 2471–2484. 
120 
 
(83) Jones, S. R., Gainetdinov, R. R., Jaber, M., Giros, B., Wightman, R. M., and Caron, M. G. 
(1998) Profound neuronal plasticity in response to inactivation of the dopamine transporter. 
Proc. Natl. Acad. Sci. 95, 4029–4034. 
(84) Park, S. S., Schulz, E. M., and Lee, D. (2007) Disruption of dopamine homeostasis 
underlies selective neurodegeneration mediated by α-synuclein: Disrupted dopamine 




Chapter 4. Application of Caged Compound Photoactivation with Fast-Scan 
Cyclic Voltammetry for Neurochemical Measurements 
 
In this chapter we describe the development of a method to quantify the liberation of 
biologically active compounds from the photo-uncaging of pHP caged compounds. Of the results 




Caged compounds are molecules that possess photoremovable protecting groups that, 
when exposed to light of the proper wavelength, intensity, and duration, are released from the 
parent molecule.
1
 It is the ability to control precise spatially and temporally resolved 
concentration changes that make the use of caged compounds so attractive to research in 
biological systems that possess highly complex spatial diversity. In order to create a caged 
compound for biological research, the molecule of interest is synthesized with photoremovable 
groups that render the compound biologically inert and remain inert until photorelease occurs.
2
 
When applied to biological systems, a good photoreleasable group should satisfy four critera: 1) 
the compound must be pure, be stable in the desired media, and the addition of the 
photoreleasable group should render the molecule biologically inactive.
1
 2) the photoreleasable 
group must release the compound of interest with high yield.  3) the group must undergo 
photolysis with light that is not of sufficient energy to damage or destroy the biological material 
(λ > 300nm).
1
 4) the byproduct of the photorelease must not interact with the biological 
material.
3
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4.1.1 A Brief History of Caged Compounds  
 The use photoactivatable compounds for biological research was pioneered primarily by 
Kaplan et al. in the 1970s (no relation) when they successfully made photoprotected ATP 
analogues and coined the term “caged”.
4
 Since their introduction, a series of photoreleasable 
groups have been synthesized and evaluated as candidates to cage a series of biological 
molecules including carboxylic acids, phosphates, sulfates, alcohols, phenols, and acids.
5
 The 
first photoreleasable group used by Kaplan et al. that continues to be the most widely used is the 
o-nitrobenzyl group.
6
 Other photoreleasable groups that have been adapted for biological 
research are benzoins, phenacyl groups, and coumaryl groups.
5
  
 As previously stated, the most widely used photoremovable protecting groups used for 
such experimentation have been o-nitrobenzyl compounds.
5,6
 The o-nitrobenzyl group has been 
most extensively used due to its relative ease of synthesis and its compatibility with multiple 
functional groups.
3
 Despite the popularity of the o-nitrobenzyl group, it fails to meet one of our 
criteria regarding being an ideal photoremovable group for biological research. The byproduct of 
the photolysis of compounds caged with the o-nitrobenzyl group is 2-nitrosobenzaldehyde is 
toxic.
3,4
 It is also the case that the photolysis of the o-nitrobenzyl group is relatively slow which 
renders it useless for researching rapid biological processes.
7
 It has therefore been the goal of  
researchers to develop novel photoreleasable groups for application in biological research and 
has been extensively reviewed.
1,2,8–21
 Specifically within the field of biological research, caged 
compounds have provided a useful means to study the brain, and have been used in vivo and ex 
vivo.
2,22–24





4.1.2 The p-Hydroxyphenacyl protecting group  
 The p-hydroxyphenacyl group (pHP, Fig. 1) was developed as a promising alternative 
photoreleasable group for use in biological systems. One attractive attribute of the pHP 
photoremovable group is that its photochemical byproduct, p-hydroxyphenylacetic acid 
(4HPAA), is non-toxic.
5,25,26
 In fact, 4HPAA is a naturally occurring byproduct of the 
metabolism of aromatic amino acids in humans and has gained interest as a biomarker for 
diseases involving nitrosative stress.
27,28
 The pHP photoremovable protecting group also 
provides advantages over other commonly used moieties, including high quantum yields, rapid 
photorelease rates, biologically inert byproducts, and high aqueous solubility.
25
 Another benefit 
to the pHP group is that the photolysis byproduct 4HPAA absorption is blue shifted from the 
incident light used for uncaging.
6
 The generation of 4HPAA after uncaging therefore will not 
interfere with the ability to quantify release. 
  
 
Figure 1. The structure of the pHP photoremovable group. 
 
The photoreaction that leads to the release of both the biomolecule of interest and 
4HPAA involves a Favorskii rearrangement (Scheme 1). This rearrangement occurs on the 
nanasecond scale,
1,26
 which also lends to its appeal for studying rapid biological processes. The 
pHP photoremovable group’s photochemistry
1,29
 and application to biological systems
1,3,6,7,26,29–
31







Scheme 1. The photorelease of X
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) has made its use 
attractive to studying neurotransmission,
32
 which as one would expect, occurs rapidly. Here, we 
demonstrate an analytical approach aimed at investigating neurotransmitter interactions that 
occur on fast timescales. We use p-hydroxyphenyl glutamate (pHP-Glu, Scheme 2) as a model 
system with the intent to be used to monitor real-time neurotransmitter actions in-vivo. pHP-Glu 






Scheme 2. The photolysis of pHP-Glu to release glutamate and 4HPAA.  
 
 
Glutamate (Glu) is an abundant, excitatory amino acid neurotransmitter in the central 
nervous system that is released by exocytosis and actively taken up by glutamate transporters.
34
  
Elevated levels of glutamate have been associated with a variety of neurological conditions and 
syndromes, including stroke,
35–40 Amyotrophic lateral sclerosis (ALS),41–47 and Alzheimer’s 
disease.
48–52
 pHp-Glu therefore offers a means to study glutamate neurotransmission with high 
spatial and temporal resolution that could be applied to researching these neurological 




4.1.4 Caged compound photoactivation in conjunction with FSCV 
The ability to quantify the amount biomolecule generated in real time upon photorelease 
has proven to be a somewhat difficult task. Here, we have offered an analytical approach for the 
quantification of Glu release via the photolysis of pHP-Glu. The photolysis of pHP-Glu yields 
two products, biologically active Glu and 4HPAA. The structure of 4HPAA is similar to the 
neurotransmitters octopamine and tyramine, which are electroactive compounds and are 
detectable by FSCV. Fast-scan cyclic voltammetry (FSCV) at carbon-fiber microelectrodes is an 
electrochemical technique often used to measure sub-second concentration changes of 




 and in vivo.
59
  
FSCV allows for the positive identification of electroactive species with high spatial and 
temporal resolution. There is therefore a spatial and temporal compatibility of FSCV and caged 
compound photoactivation.   
This compatiblity between FSCV and caged compound photoactivation has been 
exploited previously. Lee et. al. were able to increase DA concentration via the photolysis of 
caged DA while measuring D2 receptor-mediated auto-inhibition of stimulated dopamine release 
with FSCV.
60
 Although these studies are complicated by the fact that the CV generated by the 
caged form of dopamine was similar to that of uncaged dopamine, the feasibility of combining 
FSCV and caged compound photoactivation was successfully demonstrated. Here, we have 
applied this method combination as a means to indirectly quantify Glu release by quantifying 
4HPAA generation upon the photolysis of pHP-glu with FSCV.   
Additionally, recent evidence has suggested that glutamate modulates dopamine release 
with hydrogen peroxide acting as a mediator.
61–63
 Because the CV of the photoreleased by-
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product of pHP-Glu, 4HPAA, is easily distinguishable from that of DA, we are able to track this 
photoactivation process simultaneously with that of DA. This method can therefore provide the 
ability to measure neurotransmitter interaction with novel spatial and temporal resolution within 
the brain.       
 
4.2 Materials and Methods 
 
4.2.1 Materials and solutions 
pHP-Glu was synthesized by Dr. Sanjeewa Senadheera, a member of Dr. Richard Givens' 
research group at The University of Kansas, Lawrence. All other compounds used were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). All aqueous solutions were made with 
water purified to 18.2 MΩ resistances. Flow cell injection experiments were carried out in 
artificial cerebrospinal fluid (aCSF).   
 
4.2.2 Animals 
Mice (Charles River Laboratories, Inc., Wilmington, MA, USA), were housed 5 per cage 
in plastic cages with food and water available ad libitum in a temperature/humidity-controlled 
environment. Animals were placed on a 12 hour light/dark cycle.  All experiments were carried 
out in accordance with the National Institutes of Health Guide for the Care and Use of 
Laboratory Animals. All procedures were approved by the University of Kansas Institutional 




4.2.3 Electrode fabrication 
Carbon-fiber cylindrical microelectrodes were fabricated as previously described.
59,64
  
Briefly, 7µm carbon-fiber purchased from Goodfellow Cambridge Ltd. (Huntingdon, England) 
was loaded into glass capillaries (4in, 1.2mm OD; A-M Systems, Inc. Carlsborg, WA, USA) and 
pulled using a heated coil puller (Narishige International USA, East Meadow, NY, USA). 
Carbon-fiber tips were then cut with a scalpel 25 µm from the end of the glass seal. Electrodes 
were then sealed by dipping into a well-mixed epoxy mixture of  0.24g EPI-CURE 3234 Curing 
Agent (lot FCXC4114/0886GG) and 2.00g EPON Resin 815C (lot HADN0003/1307GG). 
Excess resin was removed by dipping several times in toluene and electrodes were then baked 
for 1 hour at 100°C. The electrodes were back-filled with 0.5 M potassium acetate in order to 
establish an electrical connection between the carbon-fiber and the inserted silver wire.  
   
4.2.4 Brain slices 
Brain slices were harvested as previously described 
57
. In summary, rats were deeply 
anesthetized by isofurane inhalation and decapitated. The brain was then immediately removed 
and placed into ice-cold artificial cerebral spinal fluid (aCSF). The aCSF solution contains the 
following concentrations: 2.5 mM KCl, 126 mM NaCl, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2.4 
mM CaCl2, 1.2 mM MgCl2, 20 mM HEPES, 11 mM D-glucose.  The pH was adjusted to the 
physiological pH 7.4.  To ensure the tissue received ample oxygen, the aCSF was continuously 
bubbled with 95% O2/5% CO2 throughout the experiment. After chilling for one minute the 
cerebellum was removed and the brain was bisected using a sterile razor blade.  One hemisphere 
of the brain was then glued to a plate against a cube of agar for support.  300 µm coronal brain 
slices were then obtained using a vibratome (Leica, Wetzlar, Germany). After obtaining a brain 
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slice containing striatal tissue, it was transferred to a perfusion chamber where oxygenated aCSF 
was perfused over the slice and was heated to 34 ºC.  The slice was equilibrated for one hour 
before taking any measurements. 
 
4.2.5 Uncaging set up 
Our experimental setup was adapted for voltammetry from a previous design that had 
been used for electrophysiology.
32
 A mercury lamp was used as a light source and the lamp 
output was gated using a shutter, under computer control, to a 100 µm diameter fiber optic cable 
(PolyMicro Technologies, Inc), Phoenix, AZ, held in the proper orientation by a micro-
positioner.  The fiber-optic cable was positioned near the tip of the carbon-fiber microelectrode 
by a micromanipulator.   
 
4.2.6 Electrochemical detection of pHP-Glu photoactivation in a microliter reaction vessel 
An Eppendorf pipette (epT.I.P.S.®) was inverted and clamped into position. An optical 
fiber was positioned in the pipette to allow for sample illumination. The 1mm optical fiber was 
high UV transmitting fused silica and was purchased from Polymicro Technologies. The 
microliter reaction vessel was fabricated with an inverted pipette tip that allowed for microliter 
volumes of pHP-Glu solution to be contained within the tip, held in place by the surface tension 
of the aqueous solution. This design allows for the positioning of a 1mm fiber optic cable 
directly beneath the pHP-Glu solution while inserting a CF working electrode and an Ag/AgCl 
reference electrode into the solution (Fig. 7) to allow for obtaining electrochemical 
measurements of the photo-uncaging of pHP-Glu. Once the photo-uncaging of pHP-Glu is 
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measured with FSCV, the electrodes can be removed and the sample can be removed from the 
reaction vessel for HPLC analysis. Each sample in the vessel contained 100µM pHP-Glu and 
25µM 4-methoxyphenylacetic acid internal standard in αCSF.  
 
4.2.7 HPLC analysis 
 An isocratic high performance liquid chromatography (HPLC) method was used on a 
Shimadzu Model LC 20 AD with a dual reciprocating pump and a DGV 20A3 degasser.  The 
detector was a Simadzu SPD-201V UV-VIS detector set to the wavelengths of 220 nm and 240 
nm for the detection of the pHP-Glu and 4-HPAA. The mobile phase components were (A) 99% 
water, 1% methanol and 0.06% formic acid; (B) 99% methanol, 1% water and 0.06% formic 
acid.    The flow rate was set to 1 mL/min.   
 
4.2.8 Fast scan cyclic voltammetry  
  
 4.2.8.1 Flow cell analysis  
 
FSCV measurements were collected with a custom-modified ChemClamp potentiostat 
(Dagan, Minneapolis, MN, USA) and TarHeel CV software provided by R.M. Wightman and M. 
Heien (University of North Carolina, Chapel Hill, NC, USA). For measurements taken in a flow 
cell, a six-port sample injector with manual injection was used. A cylindrical carbon fiber 
microelectrode was placed in the flow cell or microliter reaction vessel for the detection of 
analyte. A triangular waveform starting at -0.4V, scanning up to 1.0V, and back to -.4V, was 
applied to the carbon fiber microelectrode at a scan rate of 300V/s and an update rate of 10Hz 
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against a Ag/AgCl reference electrode. The measured currents were then plotted versus applied 
potential to obtain CVs of the analytes of interest. 
 
4.2.8.2 Brain slice analysis    
 Procedures for measuring DA release with background-subtracted FSCV in brain slices 
has been previously described in detail.
55, 65–67
 Briefly, a pre-calibrated cylinder carbon-fiber 
microelectrode was inserted 100µm into the brain slice using micromanipulators and a 
stereoscope. The electrode was positioned between two biphasic stimulating electrodes (A-M 
Systems Inc, Carlsborg, WA, USA) in the striatum. For DA and 4HPAA detection, a triangular 
waveform starting at -0.4V, scanning up to 1.0V, and back to -0.4V, was applied to the carbon-
fiber microelectrode at a scan rate of 300V/s and an update rate of 10 Hz. Dopamine release was 
evoked by applying a single, biphasic pulse (350 µA, 4 ms total duration). The peak current after 
stimulation was used for all release measurements, and there was a 5 minute recovery period 
between each measurement.  
 
4.2.9 Simultaneous uncaging and measuring DA in brain slices 
 Harvested striatal brain slices were obtained as previously described. For voltammetric 
recordings, a carbon fiber microelectrode and biphasic stimulating electrode were embedded 
100µm deep  into the striatum. A 100 µm diameter fiber optic cable (PolyMicro Technologies, 
Inc) was then positioned via a micropositioner near the tip of the carbon-fiber microelectrode 




4.3 Results and discussion  
4.3.1 Electrochemical detection of 4HPAA 
The temporally resolved release of biologically active glutamate is dependent on the 
photo-uncaging of pHP-Glu. Upon UV (300nm) stimulation, pHP-Glu undergoes a Favorskii 
rearrangement to release biologically active glutamate and the photo-uncaging byproduct 
4HPAA (Scheme 2). The pHP photoremovable group lends itself to use in biological systems 
due to its high quantum yield, rapid uncaging, and relative stability in biologically relevant 
solutions when compared to other conventional caged compounds.
25
 The byproduct of 
photoactivation, 4HPAA, consists of a hydroxyl group situated para to the acetate group on a 
benzene ring.  The chemical structure of this molecule prompted us to determine if we could 
measure it with FSCV.  Molecules having this similar structural arrangement have been shown to 









Figure 2. Fig. 1 Background subtracted cyclic voltammetry of the oxidation of 4HPAA (top).  
(A) Unfolded cyclic voltammogram of 100 µM 4HPAA in aCSF. The applied waveform was -
0.4 V to +1.0 V to -0.4 V at 400 V/s and 10 scans/s. The oxidation peak of 4HPAA was detected 
around  + 0.9 V on cathodic sweep. (B) The color plot (bottom) and oxidation current response 








It was determined in vitro, using flow injection analysis, that 4HPAA is readily 
detectable by FSCV and a representative cyclic voltammogram of 4HPAA can be seen in Figure 
2. The cyclic voltammogram in Fig. 2A was unfolded as to clearly delineate the forward and 
reverse scan with the switching potential in the middle of the x axis. Using a typical triangular 
waveform (-0.4V → 1.0V → -0.4V; 400 V/s), 4HPAA undergoes an irreversible oxidation near 
the switching potential on the reverse potential sweep. Since beginning this research project, 
further optimization of the quantification of 4HPAA by FSCV has recently been reported by 
Shin et al.
69
 A plot of the current response vs 4HPAA remains linear over a broad concentration 
range (R
2








4.3.2 The simultaneous detection of 4HPAA and dopamine  
The ability to rapidly release, detect, and quantify the photo-uncaging of pHP-Glu by 
measuring 4HPAA release provides us with a novel means to measure the real time interaction of 
Glu mediation on DA release in the striatum. It was hypothesized that real time glutamate 
mediated DA release could be measured by the simultaneous detection of 4HPAA and DA upon 
the photo-uncaging of pHP-Glu. The oxidation currents obtained for 4HPAA and DA using 
FSCV were determined to be resolvable in vitro using flow injection analysis with  a standard 
flow cell (Fig. 4). Note that the waveform used for the representative CV and, color plot, and 
current response in figure 4 was the optimized waveform developed by Shin et al. (-0.4 V to +1.3 
V and back to -0.4 V at a scan rate of 600 V/s).
69
 The DA oxidative peak is resolved from the 
4HPAA oxidation peak and can therefore be quantified via FSCV. The detection of 4HPAA in 
the measured in the presence of DA remains linear over a broad range of concentrations (100nM 





Table 1: Average current response vs concentration of 4HPAA in the presence of 1µM DA.   
[4HPAA] (µM) Average current (nA) 
0.1 1.995 ± 0.231 
0.5 2.483 ± 0.366 
1 2.805 ± 0.379 
10 4.217 ± 0.563 
20 7.152 ± 1.280 
50 12.314 ± 2.637 
80 16.314 ± 2.671 





Figure 4. Cyclic voltammetry of 4HPAA in the presence of 1µM DA from optimized waveform 
(-0.4 V to +1.3 V and back to -0.4 V at a scan rate of 600 V/s). (A and B) Current vs 
concentration for 4HPAA showing linear ranges from 100nM to 100µM (A) and 100nM to 20 
µM (B). Current response of the primary oxidation peak was plotted against 4HPAA 
concentration. (n=3, P=0.0091, t-test)   (C) Unfolded CV of 4HPAA and DA. The three observed 
oxidation peaks include DA oxidation and two 4HPAA oxidative peaks. (D) Color plot and 
current traces of 4HPAA and DA were obtained from a flow cell. This figure has been modified 





4.3.3 Addressing experimental concerns 
 4.3.3.1 Subtraction of pHP-Glu signal 
Exploiting the electrochemical detection of 4HPAA upon the photo-uncaging of pHP-
glutamate as a means to quantify the release of biologically active glutamate has provided certain 
challenges to be addressed. Firstly, the similarity of CVs from 4HPAA flow cell measurements 
and pHP-Glu photoactivation recordings suggested that 4HPAA liberated by the application of 
light can be effectively detected by FSCV as the reaction is occurring.  Nevertheless, it is 
important to consider that pHP-Glu itself is electroactive and also generates a CV similar to that 
of 4HPAA. The CV resulting from the uncaging of pHP-Glu must, therefore, be the result of 
subtracting the averaged CV of pHP-Glu from that of 4HPAA.  Since it is our goal to use FSCV 
as a means to quantify the amount of pHP-Glu has been photolyzed, it was necessary to confirm 
that the oxidation current from pHP-Glu could be successfully subtracted from that of 4HPAA. 
4HPAA can be electrochemically detected in mobile phase containing pHP-Glu (Fig. 5, solid 
line), and therefore confirms the faradaic oxidation peak of pHP-Glu can be successfully 
subtracted from oxidation peak of 4HPAA (Fig. 5).  We are therefore able to measure the 





Figure 5. Flow injection analysis of the subtraction of pHP-Glu oxidative current from that 
4HPAA. 100 µM pHP-Glu 100 µM 4HPAA solutions in aCSF were separately injected followed 
by an injection of 100 µM 4HPAA in the presence of 100 µM pHP-Glu (black line).     
        
4.3.3.2 The light artifact 
Another challenge to be addressed was that photo-uncaging of pHP-Glu is accompanied 
by a light artifact which can be seen in Figure 6. The light artifact is a measured current response 
resulting from the illumination of the electrode surface. This artifact therefore exists in the 
presence or absence of pHP-Glu. In order to quantify 4HPAA generation as a result of the 
photolysis of pHP-Glu the light artifact current response must be subtracted out. Possible 
interference due to the light artifact can be successfully subtracted out via background 
subtraction, therefore allowing for the direct detection of concentration changes of 4HPAA 
evolution (Figure 6). The current response attributed to a light artifact along with representative 





















CV and colorplot can be seen in Figure 6A.  The light artifact must be subtracted from the total 
measured current (Fig. 6B) to obtain the desired linear current response to the evolution of 




Figure 6. The light artifact is a current response measured as a resulting from solely illuminating 
the electrode surface. (A) Current response attributed to a light artifact along with representative 
CV and colorplot. (B) Plot of measured current vs time of light exposure for the uncaging of 
pHP-Glu solutions. (C) Current response after the subtraction of the current attributed to the light 
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4.3.4 Method validation using FSCV and HPLC  
In order validate this method described, we have developed a microliter reaction vessel 
for measuring the photo-uncaging of pHP-Glu by FSCV followed by HPLC analysis. The 
experimental setup was adapted to voltammetry from a previous design developed by Kandler et 
al. 
32
 The microliter reaction vessel was fabricated with an inverted pipette tip that allowed for 
microliter volumes of pHP-Glu solution to be contained within the tip, held in place by the 
surface tension of the aqueous solution (Fig. 7). This design allows for the positioning of a 1mm 
diameter optical fiber using a micro-positioner directly beneath the pHP-Glu solution within the 
pipette tip. The optical fiber was interfaced to a mercury lamp that was gated by a shutter under 
computer control. After setting up the microliter reaction vessel, the working electrode and 
Ag/AgCl reference electrode into the solution to take electrochemical measurements of the 






Figure 7. Photograph (left) and diagram of the fabricated microliter vessel for measuring the 
photo-uncaging of pHP-glutamate by FSCV followed by HPLC analysis. 5µL of pHP-Glu 
solution was pipetted into a pipette tip with a 1mm optical fiber place directly beneath. The 
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Once the photo-uncaging of pHP-Glu is measured with FSCV, the electrodes were 
removed (Fig 8B) and the sample solution was carefully extracted with a pipette from the 
reaction vessel for HPLC analysis. 4HPAA concentration was measured as a function of UV 
exposure time by FSCV and HPLC analysis. The data from this analysis was used to generate 
two calibration curves relating current response measured via FSCV (Fig. 9A) and 4HPAA 
concentration via HPLC to exposure time(Fig 9B). These two calibration curves were then 
combined to generate a calibration curve directly relating current response to 4HPAA 
concentration (Fig. 9C). The direct quantification of 4HPAA by FSCV released by the photolysis 






Figure 8. The process of using the microliter reaction vessel for FSCV measurements followed 
by HPLC Analysis. (A) The microliter reaction vessel with all components in place for FSCV 
measurements. (B) After taking FSCV measurements the working and reference electrodes are 
removed. (C) The sample is carefully extracted from the vessel by pipette. (D) the sample is 
transferred to an HPLC vial containing an internal standard in aCSF. (E) The sample is then 
analyzed by HPLC. 
IS in aCSF 









Figure 9. Generation of a calibration curve from the measuring the photo-uncaged of pHP-
glutamate by FSCV followed by HPLC analysis. Two calibration curves relating current 
response measured via FSCV (Fig. 9A) and 4HPAA concentration via HPLC to exposure time 





curves were then combined to generate a calibration curve directly relating current response to 
4HPAA concentration (Fig. 9C). 
4.3.5 Application to brain slice experiments   
It was the eventual goal of this study to apply this novel methodology to the brain. The 
high temporal and spatial resolution along with the ability to quantify the release of biologically 
active molecules can be applied to looking at real-time rapid biochemical interactions. Here we 
have successfully shown that we can simultaneously detect DA and 4HPAA with FSCV. As 
stated previously, it has recently been suggested that glutamate modulates dopamine release with 
hydrogen peroxide acting as a mediator.
61–63
 Specifically, it has been suggested glutamate acts at 
AMPA receptors, inhibiting striatal DA release through a mechanism mediated by hydrogen 
peroxide (H2O2). One possible application of the methodology developed here would therefore 
be to elicit this response by photo-uncaging pHP-glutamate in the striatum while simultaneously 




   
Figure 10. The uncaging of pHP-Glu and the simultaneous measurement of DA release in a 
brain slice. These measurements were taken in a coronal brain slice perfused with 200µM pHP-
Glu in aCSF. (A) The stimulating electrode and working electrode were inserted 100µm deep 
into striatal tissue and an optical fiber was positioned to illuminate the tissue directly in contact 
with the working electrode active surface. (B) Representative cyclic voltammogram with both 
DA (at 0.6 V) and 4HPAA (at 1.1V) oxidation peaks present. (C) Representative color plot and 
(D) current response to the photo-uncaging of pHP-Glu followed by electrically-evoked DA 
release taken 2 seconds after the light pulse. 
















































The next logical step was to expand upon this method and apply it to a brain slice 
experiment. Brain slices provide a nice bridge from in vitro to in vivo studies as they maintain 
much of the intact three dimensional neuroanatomical structure while providing ample surface 
area of the exposed region of interest to be accessed by our probes and solution. The 
simultaneous detection of DA and 4HPAA after the photo-uncaging of pHP-Glu was 
successfully carried out in a brain slice (Fig. 10). The light artifact from the light pulse at 5 
seconds is clearly visible on the color plot (Fig. 10C) and is similar to what has been observed in 
vitro. DA release was stimulated two seconds after the light pulse. The simultaneous detection of 
stimulated DA release and 4HPAA released from the photo-uncaging of pHP-Glu is confirmed 
by the CV obtained (Fig 10B). The successful development of this method therefore provides a 
means to quantify sub-second neurotransmitter interactions.  
It was and still is the goal of this study to apply the described method to look at Glu-DA 
interactions in vivo. Specifically, this method was applied to measure how the rapid release of 
biologically-active Glu via the photo-uncaging of pHP-Glu would impact stimulated DA release. 
Although we have successfully developed this methodology, further experiments examining how 
Glu modulates DA release in the striatum have failed to show a significant difference in 
stimulated DA release after the photo-uncaging of pHP-Glu. There are a number possibilities as 
to why we have yet to observe said result. The experiment itself is quite complex in that it 
includes the harvesting and maintenance of living tissue and the precise micropositioning of 
electrodes and optical fiber with limited space. The complexity of the experiment has also made 
it difficult to limit the amount of material (pHP-GLu) used to complete these studies. Despite 
these difficulties mentioned, we remain optimistic that this methodology will be used to 
successfully quantify the spatially resolved sub-second neurotransmitter interaction. Experiments 
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are currently being performed and optimized to look at the modulation of DA by Glu in the 
striatum.  
 
4.4 Conclusion  
 
 We have successfully developed a method to quantify the liberation of biologically active 
comounds from the photo-uncaging of pHP caged compounds. FSCV was successfully employed 
to quantify 4HPAA release in response to the photo-uncaging of pHP-Glu. The quantification of 
4HPAA indirectly allows for the quantification of the biomolecule (Glu here) release as a result 
of the photolysis. It was also demonstrated that the quantification of the liberated biomolecule as 
a result of the photo-uncaging of pHP-Glu could be measured while simultaneously quantifying 
DA concentration. This ability was demonstrated by performing in vitro studies in a microliter 
reaction vessel. The ability to quantify 4HPAA released from the photo-uncaging of pHP-Glu 
and DA by FSCV was confirmed via HPLC. This method was then successfully applied to a 
brain slice, where it was demonstrated that electrically-evoked DA release could be quantified 
while simultaneously measuring 4HPAA release after the photo-uncaging of pHP-Glu. We have 
therefore developed a novel method and provided a framework to electrochemically measure the 




4.5 References  
 
 (1) Klán, P., Šolomek, T., Bochet, C. G., Blanc, A., Givens, R., Rubina, M., Popik, V., 
Kostikov, A., and Wirz, J. (2013) Photoremovable Protecting Groups in Chemistry and Biology: 
Reaction Mechanisms and Efficacy. Chem. Rev. 113, 119–191. 
(2) Ellis-Davies, G. C. R. (2007) Caged compounds: photorelease technology for control of 
cellular chemistry and physiology. Nat. Methods 4, 619–628. 
(3) Adams, S. R., and Tsien, R. Y. (1993) Controlling cell chemistry with caged compounds. 
Annu. Rev. Physiol. 55, 755–784. 
(4) Kaplan, J. H., Forbush III, B., and Hoffman, J. F. (1978) Rapid photolytic release of 
adenosine 5’-triphosphate from a protected analog: utilization by the sodium: potassium pump of 
human red blood cell ghosts. Biochemistry (Mosc.) 17, 1929–1935. 
(5) Givens, R. S., Conrad, P. G., Yousef, A. L., Lee, J. I., Horspool, W. M., and Lenci, F. (2004) 
CRC Handbook of Organic Photochemistry and photobiology. CRC Press Boca Raton. 
(6) Pelliccioli, A. P., and Wirz, J. (2002) Photoremovable protecting groups: reaction 
mechanisms and applications. Photochem. Photobiol. Sci. 1, 441–458. 
(7) Park, C.-H., and Givens, R. S. (1997) New Photoactivated Protecting Groups. 6. p-
Hydroxyphenacyl: A Phototrigger for Chemical and Biochemical Probes1, 2. J. Am. Chem. Soc. 
119, 2453–2463. 
(8) Lawrence, D. S. (2005) The preparation and in vivo applications of caged peptides and 
proteins. Curr. Opin. Chem. Biol. 9, 570–575. 
(9) Kramer, R. H., Chambers, J. J., and Trauner, D. (2005) Photochemical tools for remote 
control of ion channels in excitable cells. Nat. Chem. Biol. 1, 360–365. 
150 
 
(10) Mayer, G., and Heckel, A. (2006) Biologically active molecules with a “light switch.” 
Angew. Chem. Int. Ed. 45, 4900–4921. 
(11) Gorostiza, P., and Isacoff, E. Y. (2008) Optical switches for remote and noninvasive control 
of cell signaling. Science 322, 395–399. 
(12) Lee, H.-M., Larson, D. R., and Lawrence, D. S. (2009) Illuminating the chemistry of life: 
design, synthesis, and applications of “caged” and related photoresponsive compounds. ACS 
Chem. Biol. 4, 409–427. 
(13) Yu, H., Li, J., Wu, D., Qiu, Z., and Zhang, Y. (2010) Chemistry and biological applications 
of photo-labile organic molecules. Chem. Soc. Rev. 39, 464–473. 
(14) Specht, A., Bolze, F., Omran, Z., Nicoud, J.-F., and Goeldner, M. (2009) Photochemical 
tools to study dynamic biological processes. HFSP J. 3, 255–264. 
(15) Schatzschneider, U. (2010) Photoactivated biological activity of transition‐metal complexes. 
Eur. J. Inorg. Chem. 2010, 1451–1467. 
(16) Priestman, M. A., and Lawrence, D. S. (2010) Light-mediated remote control of signaling 
pathways. Biochim. Biophys. Acta BBA-Proteins Proteomics 1804, 547–558. 
(17) Riggsbee, C. W., and Deiters, A. (2010) Recent advances in the photochemical control of 
protein function. Trends Biotechnol. 28, 468–475. 
(18) Krauss, U., Drepper, T., and Jaeger, K.-E. (2011) Enlightened enzymes: strategies to create 
novel photoresponsive proteins. Chem.- Eur. J. 17, 2552–2560. 
(19) Givens, R. S., Rubina, M., and Wirz, J. (2012) Applications of p-hydroxyphenacyl (pHP) 




(20) Civillico, E. F., Rickgauer, J. P., and Wang, S. S.-H. (2011) Targeting and excitation of 
photoactivatable molecules: design considerations for neurophysiology experiments, in 
Photosensitive Molecules for Controlling Biological Function, pp 7–37. Springer. 
(21) Brieke, C., Rohrbach, F., Gottschalk, A., Mayer, G., and Heckel, A. (2012) Light‐controlled 
tools. Angew. Chem. Int. Ed. 51, 8446–8476. 
(22) Callaway, E. M., and Katz, L. C. (1993) Photostimulation using caged glutamate reveals 
functional circuitry in living brain slices. Proc. Natl. Acad. Sci. 90, 7661–7665. 
(23) Wang, S. S.-H., and Augustine, G. J. (1995) Confocal imaging and local photolysis of caged 
compounds: dual probes of synaptic function. Neuron 15, 755–760. 
(24) Nerbonne, J. M. (1996) Caged compounds: tools for illuminating neuronal responses and 
connections. Curr. Opin. Neurobiol. 6, 379–386. 
(25) Givens, R. S., and Lee, J.-I. (2003) The p-hydroxyphenacyl photoremovable protecting 
group. J. Photoscience 10, 37–48. 
(26) Givens, R. S., Heger, D., Hellrung, B., Kamdzhilov, Y., Mac, M., Conrad, P. G., Cope, E., 
Lee, J. I., Mata-Segreda, J. F., Schowen, R. L., and Wirz, J. (2008) The Photo-Favorskii 
Reaction of p -Hydroxyphenacyl Compounds Is Initiated by Water-Assisted, Adiabatic Extrusion 
of a Triplet Biradical. J. Am. Chem. Soc. 130, 3307–3309. 
(27) Ischiropoulos, H. (1998) Biological tyrosine nitration: a pathophysiological function of 
nitric oxide and reactive oxygen species. Arch. Biochem. Biophys. 356, 1–11. 
(28) Takahama, U., Oniki, T., and Murata, H. (2002) The presence of 4-hydroxyphenylacetic 
acid in human saliva and the possibility of its nitration by salivary nitrite in the stomach. FEBS 
Lett. 518, 116–118. 
152 
 
(29) Givens, R. S., Rubina, M., and Wirz, J. (2012) Applications of p-hydroxyphenacyl (pHP) 
and coumarin-4-ylmethyl photoremovable protecting groups. Photochem. Photobiol. Sci. 11, 
472. 
(30) Goeldner, M., and Givens, R. (2005) Dynamic studies in biology: phototriggers, 
photoswitches and caged biomolecules. Wiley-VCH, Weinheim. 
(31) Corrie, J. E., Furuta, T., Givens, R., Yousef, A. L., and Goeldner, M. (2005) 
Photoremovable protecting groups used for the caging of biomolecules. Dyn. Stud. Biol. 
Phototriggers Photoswitches Caged Biomol. 1–94. 
(32) Kandler, K., Nguyen, T., Noh, J., and Givens, R. S. (2013) An Optical Fiber-Based 
Uncaging System. Cold Spring Harb. Protoc. 2013, pdb.top072900–pdb.top072900. 
(33) Kandler, K., Katz, L. C., and Kauer, J. A. (1998) Focal photolysis of caged glutamate 
produces long-term depression of hippocampal glutamate receptors. Nat. Neurosci. 1, 119–123. 
(34) Iversen, L., Iversen, S., Bloom, F. E., and Roth, R. H. (2008) Introduction to 
neuropsychopharmacology. Oxford University Press. 
(35) Castillo, J., Dávalos, A., Naveiro, J., and Noya, M. (1996) Neuroexcitatory amino acids and 
their relation to infarct size and neurological deficit in ischemic stroke. Stroke 27, 1060–1065. 
(36) Dávalos, A., Castillo, J., Serena, J., and Noya, M. (1997) Duration of glutamate release after 
acute ischemic stroke. Stroke 28, 708–710. 
(37) Besancon, E., Guo, S., Lok, J., Tymianski, M., and Lo, E. H. (2008) Beyond NMDA and 
AMPA glutamate receptors: emerging mechanisms for ionic imbalance and cell death in stroke. 
Trends Pharmacol. Sci. 29, 268–275. 
153 
 
(38) Sun, D. A., Sombati, S., and DeLorenzo, R. J. (2001) Glutamate Injury–Induced 
Epileptogenesis in Hippocampal Neurons An In Vitro Model of Stroke-Induced “Epilepsy.” 
Stroke 32, 2344–2350. 
(39) Bullock, R. (1995) Strategies for neuroprotection with glutamate antagonists. Ann. N. Y. 
Acad. Sci. 765, 272–278. 
(40) Castillo, J., Davalos, A., and Noya, M. (1998) Aggravation of acute ischemic stroke by 
hyperthermia is related to an excitotoxic mechanism. Cerebrovasc. Dis. Basel Switz. 9, 22–27. 
(41) Kawahara, Y., Ito, K., Sun, H., Aizawa, H., Kanazawa, I., and Kwak, S. (2004) Glutamate 
receptors: RNA editing and death of motor neurons. Nature 427, 801–801. 
(42) Bruijn, L. I., Miller, T. M., and Cleveland, D. W. (2004) Unraveling the mechanisms 
involved in motor neuron degeneration in ALS. Annu Rev Neurosci 27, 723–749. 
(43) Trotti, D., Rolfs, A., Danbolt, N. C., Brown, R. H., and Hediger, M. A. (1999) SOD1 
mutants linked to amyotrophic lateral sclerosis selectively inactivate a glial glutamate 
transporter. Nat. Neurosci. 2, 427–433. 
(44) Cleveland, D. W., and Rothstein, J. D. (2001) From Charcot to Lou Gehrig: deciphering 
selective motor neuron death in ALS. Nat. Rev. Neurosci. 2, 806–819. 
(45) Guo, H., Lai, L., Butchbach, M. E., Stockinger, M. P., Shan, X., Bishop, G. A., and Lin, C. 
G. (2003) Increased expression of the glial glutamate transporter EAAT2 modulates 
excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum. Mol. Genet. 12, 
2519–2532. 
(46) Howland, D. S., Liu, J., She, Y., Goad, B., Maragakis, N. J., Kim, B., Erickson, J., Kulik, J., 
DeVito, L., and Psaltis, G. (2002) Focal loss of the glutamate transporter EAAT2 in a transgenic 
154 
 
rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl. Acad. Sci. 
99, 1604–1609. 
(47) Vogels, O. J. M., Oyen, W. J. G., Van Engelen, B. G. M., Padberg, G., and Horstink, M. 
(1999) Decreased striatal dopamine-receptor binding in sporadic ALS: Glutamate hyperactivity? 
Neurology 52, 1275–1275. 
(48) Sheldon, A. L., and Robinson, M. B. (2007) The role of glutamate transporters in 
neurodegenerative diseases and potential opportunities for intervention. Neurochem. Int. 51, 
333–355. 
(49) Hynd, M. R., Scott, H. L., and Dodd, P. R. (2004) Glutamate-mediated excitotoxicity and 
neurodegeneration in Alzheimer’s disease. Neurochem. Int. 45, 583–595. 
(50) Maragos, W. F., Greenamyre, J. T., Penney, J. B., and Young, A. B. (1987) Glutamate 
dysfunction in Alzheimer’s disease: an hypothesis. Trends Neurosci. 10, 65–68. 
(51) Minoshima, S., Giordani, B., Berent, S., Frey, K. A., Foster, N. L., and Kuhl, D. E. (1997) 
Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann. 
Neurol. 42, 85–94. 
(52) Hyman, B. T., Van Hoesen, G. W., and Damasio, A. R. (1987) Alzheimer’s disease: 
glutamate depletion in the hippocampal perforant pathway zone. Ann. Neurol. 22, 37–40. 
(53) Heien, M. L. A. V., Johnson, M. A., and Wightman, R. M. (2004) Resolving 
Neurotransmitters Detected by Fast-Scan Cyclic Voltammetry. Anal. Chem. 76, 5697–5704. 
(54) Troyer, K. P., and Wightman, R. M. (2002) Dopamine Transport into a Single Cell in a 
Picoliter Vial. Anal. Chem. 74, 5370–5375. 
(55) Ortiz, A. N., Kurth, B. J., Osterhaus, G. L., and Johnson, M. A. (2010) Dysregulation of 
intracellular dopamine stores revealed in the R6/2 mouse striatum. J. Neurochem. 112, 755–761. 
155 
 
(56) Ortiz, A. N., Oien, D. B., Moskovitz, J., and Johnson, M. A. (2011) Quantification of 
reserve pool dopamine in methionine sulfoxide reductase A null mice. Neuroscience 177, 223–
229. 
(57) Johnson, M. A., Rajan, V., Miller, C. E., and Wightman, R. M. (2006) Dopamine release is 
severely compromised in the R6/2 mouse model of Huntington’s disease. J. Neurochem. 97, 
737–746. 
(58) Johnson, M. A., Villanueva, M., Haynes, C. L., Seipel, A. T., Buhler, L. A., and Wightman, 
R. M. (2007) Catecholamine exocytosis is diminished in R6/2 Huntington’s disease model mice. 
J. Neurochem. 103, 2102–2110. 
(59) Kraft, J. C., Osterhaus, G. L., Ortiz, A. N., Garris, P. A., and Johnson, M. A. (2009) In vivo 
dopamine release and uptake impairments in rats treated with 3-nitropropionic acid. 
Neuroscience 161, 940–949. 
(60) Lee, T. H., Gee, K. R., Ellinwood, E. H., and Seidler, F. J. (1996) Combining “caged-
dopamine” photolysis with fast-scan cyclic voltammetry to assess dopamine clearance and 
release autoinhibition in vitro. J. Neurosci. Methods 67, 221–231. 
(61) Avshalumov, M. V., Patel, J. C., and Rice, M. E. (2008) AMPA Receptor-Dependent H2O2 
Generation in Striatal Medium Spiny Neurons But Not Dopamine Axons: One Source of a 
Retrograde Signal That Can Inhibit Dopamine Release. J. Neurophysiol. 100, 1590–1601. 
(62) Avshalumov, M. V., Chen, B. T., Marshall, S. P., Peña, D. M., and Rice, M. E. (2003) 
Glutamate-dependent inhibition of dopamine release in striatum is mediated by a new diffusible 
messenger, H2O2. J. Neurosci. 23, 2744–2750. 
156 
 
(63) Bao, L., Avshalumov, M. V., Patel, J. C., Lee, C. R., Miller, E. W., Chang, C. J., and Rice, 
M. E. (2009) Mitochondria Are the Source of Hydrogen Peroxide for Dynamic Brain-Cell 
Signaling. J. Neurosci. 29, 9002–9010. 
(64) Kawagoe, K. T., Jankowski, J. A., and Wightman, R. M. (1991) Etched carbon-fiber 
electrodes as amperometric detectors of catecholamine secretion from isolated biological cells. 
Anal. Chem. 63, 1589–1594. 
(65) Ortiz, A. N., Osterhaus, G. L., Lauderdale, K., Mahoney, L., Fowler, S. C., von Hörsten, S., 
Riess, O., and Johnson, M. A. (2012) Motor function and dopamine release measurements in 
transgenic Huntington’s disease model rats. Brain Res. 1450, 148–156. 
(66) Jackson, B. P., Dietz, S. M., and Wightman, R. M. (1995) Fast-scan cyclic voltammetry of 
5-hydroxytryptamine. Anal. Chem. 67, 1115–1120. 
(67) Hashemi, P., Danoski, E., Petrovic, J., Keithley, R. B., and Wightman, R. M. (2009) 
Voltammetric Detection of 5-Hydroxytryptamine Release in the Rat Brain. Anal. Chem. 81, 
9462–9471. 
(68) Cooper, S. E., and Venton, B. J. (2009) Fast-scan cyclic voltammetry for the detection of 
tyramine and octopamine. Anal. Bioanal. Chem. 394, 329–336. 
(69) Shin, M., Kaplan, S. V., Raider, K. D., and Johnson, M. A. (2015) Simultaneous 
measurement and quantitation of 4-hydroxyphenylacetic acid and dopamine with fast-scan cyclic 





Chapter 5: Conclusions and Future Directions 
 
5.1 Chemobrain Conclusions and Future Directions.  
 
 It has been revealed that striatal DA release is attenuated in chemotherapy-treated rats. It 
is our hypothesis that this attenuated release is at least partially responsible for the negative 
effects associated with chemobrain. It was found that this impaired neurotransmitter release was 
generalized across all regions of the striatum. However, there was no significant difference in 
total DA tissue content, which suggests that DA release attenuation is not simply the result of 
massive neurodegeneration but is actually an impairment in the mechanism of release itself. We 
looked at vesicular storage by isolating and mobilizing reserve pool DA using pharmacological 
manipulation; however, no significant difference was found. 
 We have begun to elucidate the underlying physiological mechanism of chemobrain by 
studying how real-time neurotransmission may be altered by chemotherapy treatment. One 
question that can be proposed is whether or not impaired release occurs in other neurotransmitter 
systems. We have since expanded our research to look at how serotonin (5HT) release in the 
dorsal raphe nucleus may be altered in chemobrain. These first experiments have revealed that 
5HT release is also attenuated in carboplatin treated rats. There should therefore be further 
research regarding how other neurotransmitter systems may be implicated in chemobrain.  
 It should also be the goal of researchers investigating chemobrain to elucidate the 
mechanism leading to release impairments. It is interesting that a variety of chemotherapeutic 
agents cause chemobrain although many of them do not cross the blood brain barrier.
1
 Both 
blood brain barrier permeable and impermeable can induce programmed cell death and inhibit 
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neuronal repair. Whether or not metabolites enter the blood brain barrier or if changes in blood 
brain barrier permeability occur during or after chemotherapy treatment should be addressed.  
 Another possibility is that chemotherapeutic agents can inhibit neuronal signaling by 
affecting myelination. In fact, it has been found that some chemotherapeutic agents can destroy 
oligodendrocytes, which are responsible for proper myelination.
2
 investigating how 
chemotherapy may affect myelination in vitro would therefore be interesting.  
 Here, I have presented behavior measurements that involve general locomotion. It is 
imperative that more complex and rigorous behavior paradigms be completed in future studies, 
possibly in conjunction with in vivo measurements to establish that measured cognitive 
impairments correspond to electrochemical measurements. A series of behavioral paradigms 
involving learning and memory could be informative with or without simultaneous 
electrochemical measurements and include open field habituation, passive avoidance task, the 
Morris water maze, object recognition task, and differential reinforcement at lower rates.  
 The research presented here should be continued with the intention to find possible points 
of intervention regarding the alleviation or elimination of chemobrain. For instance, it is possible 
that exogenous treatment with glucocorticoid could raise endogenous DA levels in the striatum 
and could therefore could be used to alleviate or counteract the cognitive impairments associated 
with chemobrain. Oxidative stress may also play an important role in chemobrain and the ability 





5.2 Regional differences in striatal DA release in R6/2 mice conclusions and future 
directions.  
 
 In the work presented here, it was shown that electrically-evoked DA release is 
progressively attenuated in the striatum of R6/2 mice and that this attenuation is more severe in 
the dorsal striatum. Moreover, when applying a 120 stimulation pulse-train, it was found that DA 
release was only significantly attenuated in the dorsal striatum, suggesting that the ventral 
striatum is less vulnerable to the mechanism of impairment caused by the HD mutation. It was 
also found that the amount of dopamine transporter (DAT) is present in the striatum is 
significantly lower in R6/2 mice in comparison to their wild type controls. There was no regional 
difference found in DAT distribution, however. These data collectively suggest that the genetic 
mutation involved in HD leads to the increased vulnerability of the dorsal striatum in comparison 
to the ventral striatum, therefore providing insight into the disease mechanism. 
 These novel findings indeed suggest that the dorsal striatum is more vulnerable to the 
deleterious effects of HD. The next logical question would be, ’Why?’ I believe in vivo studies 
that are sensitive to could be integral in determining why these region specific susceptibilities 
occur in HD model rodents. In vivo studies would allow for the investigation of intact neuronal 
pathways that differentially innervate the striatum. 
 
5.3 Caged compound photo-activation and FSCV conclusions and future directions.  
 
  We have successfully developed a method to quantify the liberation of biologically active 
compounds from the photo-uncaging of pHP caged compounds with FSCV. FSCV was 





 It was also demonstrated that the quantification of the liberated biomolecule as a result of 
the photo-uncaging of pHP-Glu could be measured while simultaneously quantifying DA 
concentration. This method was validated with HPLC via our fabricated microliter reaction 
vessel. We then have successfully applied this method to a brain slice experiment.  
 I could not begin to address all of the potential future directions of this developed 
method. The ability to apply, release and quantify biologically active material with such high 
spatial and temporal resolution could offer nearly limitless application to future biological 
research. Although I have reported the successful development of this novel method, it is our 
initial goal is to monitor how glutamate modulates striatal DA release in real time and this work 
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